1 	|BT| (S (NP (NN Notch-1) (NN Notch-4) (JJ potent) (NN breast) (NN oncogene)) (VP (VBN overexpressed) (NP (JJ triple-negative) (NNS subtypes) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236|ES| 18:1 19:1 20:1 21:1 22:1 23:1 24:1 25:1 26:1 27:1
1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
1 	|BT| (S (NP (NNS Tumors)) (VP (VBD graded) (NP (NP (NN histology) (JJ immunostained) (NN p53)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NP (NP (NN cyclooxygenase-2) (-LRB- -LRB-) (NN Cox-2) (-RRB- -RRB-) (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN iNOS)) (-RRB- -RRB-))) (VBN sequenced) (NN p53) (NN mutation))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 8:C04 18:G05.365.590 21:G05.360.340.024.340.375.249.050 22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 28:H01.158.100.656|ES| 2:1 10:1 12:1 14:1 19:1 34:1 53:1 54:1 55:1 56:1 57:1 58:1 59:1 60:1 61:1 62:1 63:1 64:1 65:1 66:1 67:1 68:1
1 	|BT| (S (NP (DT A) (NN TRAMP/COX) (CD -2) (JJ knockout) (NN mouse) (NN model)) (ADVP (RB also)) (VP (VBD generated) (VP (VB determine) (NP (NN effect) (NN loss) (NN COX-2) (NN gene) (NN prostate) (NN tumorigenesis) (NN TRAMP) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 29:B01.050.050.136.500.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 34:A05.360.444.575|ES| 5:1 9:1 19:1 32:1 52:1 69:1 70:1 71:1 72:1 73:1 74:1 75:1 76:1 77:1 78:1 79:1
1 	|BT| (NP (NP (JJ Aberrant) (NN methylation) (NN SPARC) (NN gene) (NN promoter) (JJ clinical) (NN implication) (JJ gastric) (NN cancer))) |ET| |BS|35:G02.111.570.080.689.675 36:G02.111.087.029.538 37:D12.776.157.125.715|ES| 9:1 18:1 19:1 80:1 81:1 82:1 83:1 84:1 85:1 86:1
1 	|BT| (NP (NP (NP (NN Activation) (JJ p53-dependent) (NN apoptosis) (JJ acute) (NN ablation) (NN glycogen) (NN synthase) (NN kinase-3beta)) (NP (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 41:A11|ES| 17:1 18:1 19:1 66:1 87:1 88:1 89:1 90:1 91:1 92:1 93:1 94:1
1 	|BT| (S (NP (JJ Aldo-keto) (NN reductase) (NN family) (CD 1) (NN B10) (NN gene) (NN silencing)) (VP (VBP result) (NP (NP (NN growth) (NN inhibition) (JJ colorectal) (NN cancer) (NN cell)) (: :) (NP (NP (NN Implication) (NN cancer)) (NN intervention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 42:G05.355.315.203.374 43:F01.145.544 44:F01.829.263 45:G07.700.320.249|ES| 9:1 17:1 18:1 19:1 94:1 95:1 96:1 97:1 98:1 99:1 100:1 101:1 102:1 103:1 104:1 105:1 106:1
1 	|BT| (FRAG (SBAR (IN Although) (S (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (ADVP (RB morphologically)) (VP (VBZ resembles) (NP (NP (NN colon)) (, ,) (NP (NN CDX2) (NN expression))) (NP (ADJP (RB apparently) (JJR lower)) (JJ normal) (NN colon)))))) |ET| |BS|46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589|ES| 2:1 19:1 107:1 108:1 109:1 110:1 111:1 112:1 113:1 114:1 115:1 116:1 117:1 118:1
1 	|BT| (S (NP (NN Analysis) (JJ colorectal) (NN cancer) (NN patient) (NN cohort)) (VP (VBZ establishes) (SBAR (S (NP (NN HNF4alpha)) (ADVP (RB significantly)) (VP (VBD upregulated) (NP (VBN compared) (NP (JJ adjacent) (JJ normal) (JJ epithelial) (NN resection)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 49:E05.318.760.500.750 50:M01.643|ES| 17:1 18:1 19:1 50:1 118:1 119:1 120:1 121:1 122:1 123:1 124:1 125:1 126:1 127:1 128:1
1 	|BT| (S (NP (NN Animal) (NN breast) (NN colon) (NN tumor) (NN therapy) (NN study)) (VP (VBD showed) (SBAR (S (NP (JJ 15-PGDH) (NN gene) (NN therapy)) (VP (VBD produced) (NP (JJ significant) (NN delay) (NN 2LMP) (NN LS174T) (NN tumor) (NN growth))))))) |ET| |BS|8:C04 10:A01.236 19:B01.050 45:G07.700.320.249 51:C04.588.274.476.411.307.180 52:E02|ES| 7:1 9:1 19:1 23:1 102:1 113:1 129:1 130:1 131:1 132:1 133:1 134:1 135:1 136:1 137:1 138:1
1 	|BT| (S (NP (NN Antagonism) (NN miR-221) (NN miR-222)) (VP (VBZ reduces) (NP (NN growth) (NN colon) (NN tumor) (NN mouse) (NN colitis)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 51:C04.588.274.476.411.307.180 53:C06.405.205.265|ES| 7:1 19:1 52:1 102:1 113:1 139:1 140:1 141:1 142:1 143:1
1 	|BT| (S (NP (NP (JJ Antisense) (NNS oligodeoxynucleotides) (JJ human) (NN superoxide) (NN dismutase) (CD 2)) (CC and/or) (NP (JJ ectopic) (NN bcl-2) (NN overexpression))) (VP (VBD avoided) (NP (NP (NNS polyphenols)) (SBAR (S (NP (JJ chemoradiotherapy-induced) (JJ colorectal) (NN cancer) (NN elimination)) (VP (VBD showed) (NP (NP (JJ mangano-type) (NN superoxide) (NN dismutase) (NN Bcl-2) (JJ key) (NN target) (JJ molecular) (NN mechanism)) (VP (VBN activated) (NP (JJ combined) (NN application) (NN t-PTER) (NNP QUER)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 56:D02.455.426.559.389.657.715 57:D13.695.578.424.450 58:D08.811.682.881 59:E02.186.079|ES| 17:1 18:1 19:1 36:1 132:1 144:1 145:1 146:1 147:1 148:1 149:1 150:1 151:1 152:1 153:1 154:1 155:1 156:1 157:1 158:1 159:1 160:1 161:1 162:1 163:1 164:1 165:1 166:1 167:1
1 	|BT| (FRAG (PP (IN As) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (VP (VBN associated) (NP (NP (JJR higher) (NN risk) (JJ gastric) (NN cancer)) (, ,) (NP (JJR lower) (NN CDX2) (NN expression)) (VP (VBD compared) (NP (NP (JJ complete) (JJ intestinal) (NN metaplasia) (JJ normal) (NN colon) (NN epithelium)) (VP (VBN resolved) (NP (NP (JJ current) (NN contradiction) (JJ tumor-suppressive) (NN role)) (NN CDX2) (NN colon) (JJ high) (NN prevalence) (NN CDX2) (JJ intestinal) (NN metaplasia)))))))))) |ET| |BS|8:C04 15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 60:E05.318.308.985.525.750 61:E05.318.740.600.800 62:A10.272|ES| 2:1 18:1 19:1 31:1 50:1 86:1 108:1 109:1 110:1 113:1 114:1 115:1 117:1 118:1 168:1 169:1 170:1 171:1 172:1 173:1 174:1 175:1 176:1 177:1 178:1 179:1
1 	|BT| (S (PP (IN As) (NP (JJ key) (NN molecule) (NN drive) (NN progression) (NN chemoresistance) (JJ gastrointestinal) (NN cancer))) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN HER2)) (VP (VBP become) (NP (JJ efficacious) (NN drug) (NN target) (NN setting)))) |ET| |BS|16:C23.550.291.656 63:G05.360.340.024.340.375.500.791.295.305 64:D08.811.913.696.620.682.725.400.009.300 65:D08.811.913.696.620.682.725.400.009.400 66:F01.658.293 67:D26|ES| 2:1 10:1 14:1 18:1 19:1 48:1 102:1 159:1 160:1 168:1 180:1 181:1 182:1 183:1 184:1 185:1 186:1 187:1 188:1 189:1 190:1 191:1 192:1
1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 201:1 202:1 203:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD decreased) (NP (NP (JJ human) (JJ gastric) (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN dysplasia) (NN cancer))))) |ET| |BS|33:C04.697.098 47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 114:1 115:1 159:1 201:1 202:1 203:1 204:1 205:1 206:1 207:1
1 	|BT| (S (NP (NN CDX2) (NN expression)) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (JJ incomplete) (JJ intestinal) (NN metaplasia)) (, ,) (NP (VBP express) (NP (NP (JJ gastric) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC5AC) (NN MUC6)) (-RRB- -RRB-))) (JJ intestinal) (NP (NP (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-)))) (, ,)) (VP (VBD compared) (NP (JJ complete) (JJ intestinal) (NN metaplasia))) (, ,) (S (VP (VBP express) (NP (NP (JJ intestinal) (NN mucin)) (PRN (-LRB- -LRB-) (NP (NN MUC2)) (-RRB- -RRB-))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 71:D12.776.395.560.631 72:D12.776.395.560.631.100|ES| 2:1 10:1 14:1 19:1 50:1 86:1 108:1 109:1 110:1 114:1 115:1 124:1 172:1 202:1 208:1 209:1 210:1 211:1 212:1
1 	|BT| (S (S (NP (NN Cdx2)) (VP (VBZ induces) (NP (NN differentiation) (JJ intestinal) (JJ epithelial) (NN cell) (NN vitro)))) (: ;) (S (ADVP (RB therefore)) (, ,) (VP (VBD sought) (VP (VB establish) (SBAR (IN whether) (S (NP (JJ causal) (NN relationship)) (VP (VBZ exists) (NP (NN Cdx2) (NN activation) (JJ intestinal) (NN metaplasia))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 73:N05.715.350.200 74:G04.299.151 75:A11.436|ES| 2:1 19:1 94:1 109:1 110:1 127:1 213:1 214:1 215:1 216:1 217:1 218:1 219:1 220:1 221:1 222:1 223:1 224:1 225:1
1 	|BT| (NP (NP (NP (NN CDX2)) (, ,) (NP (NP (JJ human) (NN homologue)) (NP (FW Drosophila) (FW caudal))) (, ,)) (NP (VBN mutated) (NN allele) (NN replication) (NN error) (JJ positive) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 76:B01.050.500.131.617.289.310.250 77:G05.360.340.024.340.030 78:G02.111.087.222|ES| 2:1 17:1 18:1 19:1 36:1 114:1 226:1 227:1 228:1 229:1 230:1 231:1 232:1 233:1
1 	|BT| (S (NP (NP (NN CDX2)) (, ,) (NP (NN master) (NN regulator) (JJ intestinal) (NN phenotype)) (, ,)) (VP (VBN shown) (NP (NN play) (JJ tumor-suppressive) (NN role) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 51:C04.588.274.476.411.307.180 79:I03.450.642.693 80:G05.695|ES| 2:1 18:1 19:1 31:1 109:1 113:1 114:1 177:1 234:1 235:1 236:1 237:1 238:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NP (JJ Gastric) (NN expression) (NN Cdx2)) (ADJP (RB alone) (JJ sufficient))) (VP (VBP induce) (NP (JJ intestinal) (NN metaplasia) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 52:1 104:1 109:1 110:1 115:1 213:1 239:1 240:1 241:1 242:1 243:1
1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN In) (NP (JJ human) (NN CRC) (NN cell))) (, ,) (NP (NN miR-221) (NN miR-222)) (VP (VBP act) (NP (JJ positive) (NN feedback) (NN loop) (NN increase) (NN expression) (NN level) (NN RelA) (NN STAT3)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 82:D12.644.360.024.342.300 83:L01.143.283.425|ES| 2:1 19:1 36:1 40:1 94:1 104:1 115:1 140:1 141:1 233:1 239:1 244:1 245:1 246:1 247:1 248:1 249:1 250:1 251:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (UCP (PP (IN In) (NP (NN mouse))) (, ,) (NP (NP (NN fucosylation) (NN deficiency) (NN lead) (NN colitis) (NN adenocarcinoma)) (, ,) (NP (NN loss) (NN Notch) (NN activation)) (, ,) (NP (NN down-regulation) (NN Hes1))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 84:C04.557.470.200.025 85:G02.111.087.225 86:D01.268.556.435 87:C18.654.521|ES| 2:1 19:1 32:1 52:1 104:1 143:1 225:1 239:1 244:1 252:1 253:1 254:1 255:1 256:1 257:1 258:1
1 	|BT| (S (NP (JJ Correlated) (NN pattern)) (VP (VBN observed) (NP (NP (NN HNF4alpha) (NN Cdx2) (JJ several) (JJ experimental) (NN model) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (: :) (NP (NP (NN xenograft) (JJ nude) (NN mouse)) (, ,) (NP (NN wound) (NN healing) (NN glucose) (NN starvation)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 89:G16.100.856.891 90:C18.654.521.750 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 94:A11.251.210 95:E05.599|ES| 2:1 18:1 19:1 36:1 52:1 72:1 94:1 104:1 113:1 123:1 213:1 259:1 260:1 261:1 262:1 263:1 264:1 265:1 266:1 267:1 268:1 269:1 270:1
1 	|BT| (S (S (NP (NN CRC) (NN patient)) (VP (VBD decreased) (NP (NN level) (NN miR-195-5p) (NN tumor) (NN tissue))) (S (ADVP (RB significantly)) (VP (VBD shortened) (SBAR (S (NP (NN survival)) (VP (VBD revealed) (NP (NP (NP (NN TCGA) (NN colon) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NN COAD)) (-RRB- -RRB-))) (NN dataset) (NN CRC) (NN cohort))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 46:A03.556.124.526.356 50:M01.643 84:C04.557.470.200.025 96:I03.784 97:V02.302 98:A10|ES| 7:1 10:1 14:1 19:1 113:1 120:1 121:1 124:1 202:1 245:1 249:1 255:1 271:1 272:1 273:1 274:1 275:1 276:1 277:1 278:1
1 	|BT| (S (S (VP (VBG Crossing) (NP (NP (NP (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NP (NP (NN mouse) (JJ prone) (JJ spontaneous) (JJ intestinal) (NN tumor) (NN development) (NN pCdx2-9LacZ)) (NP (JJ transgenic) (NN mouse) (S (VP (VBG containing) (NP (NN LacZ) (NN reporter) (NN control) (JJ 9.3-kb) (NN Cdx2) (NN promoter))))))))) (VP (VBD showed) (SBAR (S (NP (NN promoter) (NN segment)) (VP (VBZ contains) (NP (NP (NN sequence)) (VP (VBG recapitulating) (NP (NN decrease) (NN Cdx2) (NN expression) (JJ intestinal) (NN cancer))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 26:G02.111.570.080 99:B01.050.050.136.500 100:G05.360.340.024.686.545 101:C04.588.274.476.411 102:C04.588.274.476.411 103:G11.427.695.525|ES| 7:1 10:1 14:1 18:1 19:1 35:1 52:1 83:1 109:1 115:1 132:1 213:1 279:1 280:1 281:1 282:1 283:1 284:1 285:1 286:1 287:1 288:1 289:1 290:1 291:1 292:1 293:1 294:1 295:1
1 	|BT| (S (NP (NN Downregulation) (NN miR-610)) (VP (VBZ promotes) (SBAR (S (NP (NN proliferation) (NN tumorigenicity)) (VP (VBZ activates) (NP (NN Wnt/beta-catenin) (NN signaling) (JJ human) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 105:G02.149.115.800.925|ES| 19:1 36:1 195:1 296:1 297:1 298:1 299:1 300:1 301:1 302:1 303:1 304:1
1 	|BT| (S (NP (JJ Ectopic) (NN expression) (NN miR-139-5p) (NN colon) (NN cancer) (NN cell) (NN line)) (VP (ADVP (RB significantly)) (NP (VBD suppressed) (NP (NP (NN cell) (NN growth) (VBN evidenced) (NN cell) (NN viability) (NN assay)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.001)))) (-RRB- -RRB-))) (NP (NP (NP (NN colony) (NN formation) (NN assay)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))) (NP (NP (NN xenograft) (NN tumor) (NN growth) (JJ nude) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (NN P)) (ADJP (JJR <) (NP (CD 0.01)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 20:G03.495 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 107:G05.355.315.202 108:G04.299.316 109:I01.696.116|ES| 7:1 10:1 14:1 18:1 19:1 43:1 52:1 94:1 102:1 113:1 115:1 124:1 264:1 265:1 266:1 305:1 306:1 307:1 308:1 309:1 310:1 311:1 312:1 313:1 314:1 315:1
1 	|BT| (NP (NP (NN Expression) (JJ gut-enriched) (JJ Kruppel-like) (NN factor)) (FRAG (-LRB- -LRB-) (NP (NP (JJ Kruppel-like) (NN factor) (CD 4) (-RRB- -RRB-) (NN gene)) (JJ human) (ADJP (NN colon) (NN cancer) (NN cell) (NN line) (NN RKO) (JJ dependent)) (NN CDX2)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210|ES| 9:1 10:1 14:1 18:1 19:1 36:1 94:1 113:1 114:1 185:1 264:1 316:1 317:1 318:1 319:1 320:1 321:1
1 	|BT| (S (NP (NN Expression) (NN KLK13) (NN KLK14) (NN gene)) (VP (VBN examined) (NP (NP (NN mRNA) (NN protein) (NN level) (NN cohort) (CD 57) (NN patient)) (NP (NP (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 110:C04.588.894.797.520.109.220.249 111:D13.444.735.544 112:D12.776.097.820|ES| 4:1 9:1 10:1 14:1 18:1 19:1 120:1 121:1 249:1 316:1 322:1 323:1 324:1 325:1 326:1 327:1 328:1 329:1
1 	|BT| (S (NP (JJ Further) (NN decrease) (NN CDX2) (NN expression) (JJ gastric) (NN dysplasia) (NN cancer)) (VP (VBZ suggests) (NP (NP (NN CDX2) (NN play) (JJ similar) (JJ anticarcinogenic) (NN role)) (JJ intestinal) (NN metaplasia) (NN colon)))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 47:A03.556.124 48:C23.550.589 70:A03.556.875.875 79:I03.450.642.693|ES| 18:1 19:1 31:1 86:1 109:1 110:1 113:1 114:1 115:1 203:1 238:1 295:1 330:1 331:1 332:1 333:1
1 	|BT| (FRAG (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ high) (NN uniform) (NN expression) (NN CDX2)) (NP (NP (JJ characteristic) (JJ metastatic) (JJ colorectal) (NN cancer)) (, ,) (NP (ADJP (ADJP (JJ weak)) (CC and/or) (ADJP (JJ focal))) (NN CDX2) (NN expression) (JJ alert) (JJ surgical) (NN pathologist) (NN possibility) (JJ primary) (NN lung) (NN adenocarcinoma)) (, ,) (NP (ADVP (RB especially)) (NN presence) (NN goblet) (NN cell) (NN morphology))))) |ET| |BS|113:C04.697.650 114:J01.637.215 115:E04|ES| 2:1 17:1 18:1 19:1 94:1 114:1 115:1 149:1 178:1 255:1 328:1 334:1 335:1 336:1 337:1 338:1 339:1 340:1 341:1 342:1 343:1 344:1 345:1 346:1 347:1 348:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN Cdx2)) (VP (VBD decreased) (S (VP (VBG knocking) (NP (NN HNF4alpha) (JJ human) (NN colon) (NN cancer) (NN cell)) (S (VP (VBG using) (NP (NN siRNA) (NN colon) (NN mouse))))))) (S (ADVP (RB conditionally)) (VP (VBD knocked) (NP (NN Hnf4alpha) (NN gene) (JJ adult) (NN intestine)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN Hnf4alpha)) (PRN (-LRB- -LRB-) (NP (NN f/f)) (-RRB- -RRB-))) (: ;) (NP (NNP VilCre) (-LRB- -LRB-) (NN ERT2) (-RRB- -RRB-) (NN mouse))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 41:A11 46:A03.556.124.526.356 47:A03.556.124 55:B01.050.150.900.649.801.400.112.400.400 116:D08.811.913.696.620.682.700.567.249.750 117:D13.150.650.700 118:D01.248.497.158.380 119:M01.060.116|ES| 2:1 9:1 10:1 14:1 18:1 19:1 36:1 52:1 94:1 113:1 123:1 202:1 213:1 217:1 334:1 349:1 350:1 351:1 352:1 353:1 354:1 355:1 356:1 357:1 358:1 359:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ stable) (NN overexpression)) (VP (VBG using) (NP (JJ lentiviral) (NN vector) (NN NCI-H460) (NN A549) (NN cell)))) (VP (VBD inhibited) (NP (NN tumor) (NN xenograft) (NN growth) (JJ immunodeficient) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (ADJP (CD 50) (NN %)) (NN reduction)) (VP (VBN compared) (NP (NN control)) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))) (, ,) (PP (IN whereas) (NP (NP (NP (NN effect) (NN mir-660) (NN overexpression) (JJ absent) (NN H1299)) (, ,) (NP (NP (NN lung) (NN cancer) (NN cell) (NN line)) (VP (VBG lacking) (NP (NN p53) (NN locus))))) (, ,) (NP (ADJP (FW vitro) (FW vivo)) (NN assay))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 11:B01.050.150.900.649.865.635.505.500 41:A11 45:G07.700.320.249 92:E04.936.764 93:A01.941.875 94:A11.251.210 106:E05.091 120:I01.409.418.750.600.480.150 121:B04.820.650.589 122:C14.280.383 123:G05.360.337 124:C20.673|ES| 2:1 7:1 10:1 12:1 14:1 18:1 19:1 50:1 52:1 75:1 94:1 102:1 152:1 216:1 264:1 265:1 289:1 310:1 328:1 334:1 350:1 360:1 361:1 362:1 363:1 364:1 365:1 366:1 367:1 368:1 369:1 370:1 371:1 372:1 373:1 374:1 375:1 376:1 377:1 378:1
1 	|BT| (S (NP (NN gamma-Secretase) (NN inhibitor)) (VP (VBP abrogate) (NP (NP (JJ oxaliplatin-induced) (NN activation) (NN Notch-1) (NN signaling) (NN pathway) (NN colon) (NN cancer) (NN cell)) (VP (VBG resulting) (NP (VBN enhanced) (NN chemosensitivity)))))) |ET| |BS|41:A11 69:G02.111.087.800 125:D08.811.277.656.300.032 126:G02.111.087.800|ES| 18:1 19:1 20:1 94:1 113:1 195:1 225:1 379:1 380:1 381:1 382:1 383:1 384:1 385:1 386:1
1 	|BT| (NP (NP (NP (NN Germline) (JJ somatic) (NN mutation) (NN BER) (NN gene)) (, ,) (NP (NP (NN MutY) (NN Homolog)) (PRN (-LRB- -LRB-) (NP (NN MUTYH/MYH)) (-RRB- -RRB-))) (NP (NP (JJ DNA-directed) (NN polymerase)) (PRN (-LRB- -LRB-) (NP (NN POLB)) (-RRB- -RRB-))) (, ,)) (NP (VBN associated) (VBN increased) (NN risk) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 61:E05.318.740.600.800 127:D08.811.913.696.445.308.300 128:E02.095.301 129:G02.111.087.219 130:A05.360.490|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 34:1 47:1 169:1 171:1 387:1 388:1 389:1 390:1 391:1 392:1 393:1 394:1 395:1
1 	|BT| (S (NP (NN HDAC8) (NN STAT3)) (VP (VBP repress) (NP (NN BMF) (NN gene) (NN activity) (NN colon) (NN cancer) (NN cell)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 41:A11 46:A03.556.124.526.356 82:D12.644.360.024.342.300|ES| 9:1 18:1 19:1 94:1 113:1 251:1 396:1 397:1 398:1 399:1
1 	|BT| (NP (NP (ADJP (RB Here) (VBN studied)) (NN role) (NN HNF4alpha) (NN mechanism) (NN deregulation) (NN Cdx2) (NN colon) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 18:1 19:1 31:1 113:1 123:1 162:1 213:1 400:1 401:1 402:1
1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NP (NN role) (NN Bcl-3) (NN azoxymethane/dextran) (NN sulfate) (NN sodium)) (PRN (-LRB- -LRB-) (NP (NN AOM/DSS)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (NP (NP (NN colon) (NN tumor)) (, ,) (NP (NN mouse) (NN model) (JJ colitis-associated) (JJ colorectal) (NN cancer)) (JJ human)))) |ET| |BS|4:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 51:C04.588.274.476.411.307.180 53:C06.405.205.265 55:B01.050.150.900.649.801.400.112.400.400 131:D09.698.365.272.300 132:D02.172.080|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 52:1 72:1 113:1 400:1 403:1 404:1 405:1 406:1 407:1 408:1 409:1 410:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBD investigated) (NP (NP (NN cell) (NN death) (NN signaling) (NN mechanism)) (VP (VBD induced) (NP (NN PGG) (JJ human) (NN prostate) (NN cancer) (NN cell) (JJ different) (NN p53) (JJ functional) (NN status)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 133:D01.248.497.158.685.750.744.600 134:G04.299.139 135:C23.550.260|ES| 2:1 12:1 18:1 19:1 36:1 77:1 94:1 162:1 195:1 400:1 403:1 411:1 412:1 413:1 414:1 415:1 416:1
1 	|BT| (FRAG (ADVP (RB Here)) (, ,) (NP (NP (NN report) (ADJP (RB inversely) (JJ related)) (NN expression) (NN miR-137) (NN CAR) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell)) (, ,) (SBAR (WHADVP (WRB wherein)) (S (NP (NN miR-137)) (VP (VBD downregulated) (NP (JJ resistant) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320 139:J01.937.500.100|ES| 2:1 19:1 94:1 115:1 400:1 417:1 418:1 419:1 420:1 421:1 422:1 423:1 424:1 425:1 426:1 427:1
1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBP show) (SBAR (S (NP (NNP NANOG)) (VP (VBD expressed) (NP (NP (NN NANOG1) (NN NANOGP8) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-)))))))) |ET| |BS|4:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 6:1 10:1 14:1 17:1 18:1 19:1 36:1 245:1 428:1 429:1 430:1 431:1 432:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NP (JJ molecular) (NN detail)) (VP (VBG underlying) (NP (NP (NN miR-146a) (JJ mediated) (NN regulation) (NN target) (NN gene) (JJ precise) (JJ biological) (NN function) (NN cancer)) (, ,) (NP (NP (RB especially) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) (VP (VBZ remains) (ADJP (JJ unclear)))) |ET| |BS|104:C04.557.470.200.025.255 140:G05.355.315 141:G16.100|ES| 2:1 9:1 10:1 14:1 18:1 19:1 33:1 160:1 161:1 303:1 304:1 345:1 433:1 434:1 435:1 436:1 437:1 438:1 439:1 440:1 441:1 442:1 443:1
1 	|BT| (NP (NP (NP (NP (JJ Human) (NN CRC) (NN tissue)) (NP (JJR higher) (NN level) (NN miR-221) (NN miR-222) (JJ nontumor) (NN colon) (NN tissue))) (: ;) (NP (NN increase)) (VP (VBD correlated) (NP (VBN increased) (NN level) (NN RelA) (NN STAT3) (NNS mRNAs))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544|ES| 19:1 40:1 47:1 113:1 140:1 141:1 170:1 217:1 245:1 249:1 250:1 251:1 272:1 444:1 445:1 446:1 447:1
1 	|BT| (S (NP (NN Hypermethylation) (NN miR-137) (NN promoter) (JJ negative) (NN regulation) (NN miR-137) (NN CAR)) (VP (VP (VBP contribute) (NP (NP (NN part)) (VP (VBD reduced) (NP (NN miR-137) (NN expression))))) (VP (VBD increased) (NP (NN CAR) (NN MDR1) (NN expression) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 142:I01.880.604|ES| 19:1 47:1 83:1 94:1 115:1 420:1 421:1 423:1 424:1 438:1 448:1 449:1 450:1 451:1 452:1 453:1
1 	|BT| (NP (NP (NP (NN Immunohistochemistry) (NN beta-catenin)) (, ,) (NP (NN c-myc)) (, ,) (NP (NP (NN Ki-67) (NN TUNEL-staining)) (VP (VBN performed) (VP (VBP investigate) (NP (NP (NN TQ) (POS 's)) (NN effect) (JJ major) (JJ colorectal) (NN cancer) (NN pathway))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 143:E01.370.225.500.607.512 144:E05.393.475|ES| 2:1 17:1 18:1 19:1 60:1 75:1 383:1 454:1 455:1 456:1 457:1 458:1 459:1 460:1 461:1 462:1
1 	|BT| (S (PP (IN In) (NP (JJ nude) (NN mouse) (NN xenograft) (NN model))) (, ,) (NP (NN overexpression) (NN miR-141) (NN knockdown) (NN MAP4K4)) (ADVP (RB significantly)) (VP (VBD repressed) (NP (JJ pancreatic) (NN cancer) (NN cell) (NN growth)))) |ET| |BS|41:A11 45:G07.700.320.249 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875|ES| 2:1 18:1 19:1 52:1 72:1 94:1 102:1 124:1 152:1 244:1 265:1 266:1 463:1 464:1 465:1 466:1 467:1
1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PIM) (NN kinase)) (VP (VBP activate) (S (NP (NN MYC) (NN signaling) (NN mRNA) (NN translation) (NN prostate) (NN cancer)) (VP (VBP cooperate) (S (NP (NN MYC)) (VP (VB accelerate) (NP (NN tumorigenesis)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 69:G02.111.087.800 145:G02.111.087.675.871|ES| 2:1 18:1 19:1 77:1 78:1 195:1 244:1 325:1 468:1 469:1 470:1 471:1 472:1 473:1 474:1 475:1
1 	|BT| (S (PP (IN In) (NP (JJ current) (NN report))) (, ,) (VBN used) (S (NP (NN DLD-1) (JJ colorectal) (NN cancer) (NN cell)) (ADVP (RB stably)) (NP (VBN transfected) (NP (NN POX) (NN gene) (NN control) (JJ tetracycline-inducible) (NN promoter))) (VP (VBD found) (SBAR (S (NP (CD three) (NN pathway) (NN cross) (NN talk)) (VP (VBD downregulated) (NP (NP (NN POX)) (: :) (NP (NP (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NN pathway)) (, ,) (NP (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN pathway) (NN Wnt/beta-catenin) (NN pathway)))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 23:D12.776.091.249 24:D08.811.600.720.750 41:A11 64:D08.811.913.696.620.682.725.400.009.300 146:D02.455.426.559.847.562.900.875 147:G02.149.115.800.925 148:G12.425.143.281|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 37:1 61:1 76:1 83:1 94:1 102:1 104:1 175:1 184:1 185:1 186:1 187:1 244:1 289:1 302:1 383:1 417:1 426:1 476:1 477:1 478:1 479:1 480:1 481:1 482:1 483:1 484:1
1 	|BT| (NP (NP (PP (IN In) (NP (JJ particular))) (, ,) (NP (NP (NN expression) (JJ intestine-specific) (NN transcription) (NN factor) (NN Cdx2)) (, ,) (NP (JJ key) (NN gene) (JJ intestinal) (NN identity)) (VP (VBD downregulated) (NP (NP (JJ invasive) (NN cancer) (NN cell)) (, ,) (VP (VBD reduced) (NP (NN wound) (NN healing) (NN vitro)))))))) |ET| |BS|41:A11 47:A03.556.124 89:G16.100.856.891 149:G05.360.340.024.340.364.875.890|ES| 2:1 9:1 18:1 19:1 94:1 109:1 115:1 159:1 185:1 213:1 216:1 244:1 267:1 268:1 426:1 452:1 485:1 486:1 487:1 488:1 489:1
1 	|BT| (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NN colon) (NN cancer) (NN cell)) (VP (MD may) (VP (VB up-regulate) (NP (NN Notch-1) (JJ protective) (NN mechanism) (NN response) (NN chemotherapy))))) |ET| |BS|41:A11 150:Z01.542.248.960 151:E02.319|ES| 2:1 18:1 19:1 20:1 94:1 113:1 162:1 244:1 490:1 491:1 492:1 493:1 494:1 495:1
1 	|BT| (FRAG (PP (IN In) (NP (JJ adult))) (, ,) (NP (NP (JJ Cdx1) (NN Cdx2)) (, ,) (NP (NN Cdx4)) (, ,) (NP (ADJP (RB intensively) (VBN explored)) (NN function) (JJ intestinal) (NN tissue) (NN homeostasis) (NN pathogenesis) (JJ gastrointestinal) (NN cancer)))) |ET| |BS|47:A03.556.124 98:A10 119:M01.060.116 152:G07.700.345|ES| 2:1 18:1 19:1 33:1 109:1 183:1 213:1 244:1 272:1 355:1 496:1 497:1 498:1 499:1 500:1 501:1
1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBP demonstrate) (S (NP (NP (NP (NN histone) (NN deacetylase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN HDACi)) (-RRB- -RRB-))) (NN vorinostat) (NN LBH589)) (VP (ADVP (RB significantly)) (VBP downregulate) (NP (NN TS) (NN gene) (NN expression) (NN panel) (NN colon) (NN cancer) (NN cell) (NN line)))))) |ET| |BS|94:A11.251.210 153:D27.505.519.389.360 154:Z01.058.266.887 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 18:1 19:1 94:1 113:1 115:1 124:1 131:1 244:1 264:1 380:1 502:1 503:1 504:1 505:1 506:1 507:1 508:1 509:1 510:1
1 	|BT| (FRAG (PP (IN In) (NP (NN study))) (, ,) (NP (VBN explored) (NN role) (NN miR-141) (JJ pancreatic) (NN cancer))) |ET| |BS|15:F01.829.316.616|ES| 2:1 18:1 19:1 31:1 131:1 244:1 463:1 467:1 499:1
1 	|BT| (FRAG (NP (ADVP (FW In) (FW vitro)) (PRN (, ,) (NP (NP (VBN forced) (NN expression) (NN Cdx2) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line)) (SBAR (S (NP (VBN retarded) (NN wound) (NN repair)) (VP (VBD reduced) (NP (NN migration)))))) (, ,))) (SBAR (IN whereas) (S (NP (NN inhibition) (NN Cdx2) (NN expression) (NN RNA) (NN interference)) (VP (VBD enhanced) (NP (NN migration)))))) |ET| |BS|43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 89:G16.100.856.891 94:A11.251.210 122:C14.280.383 156:G05.355.315.203.374.790|ES| 2:1 18:1 19:1 36:1 94:1 103:1 113:1 115:1 213:1 216:1 244:1 264:1 267:1 372:1 385:1 452:1 511:1 512:1 513:1 514:1 515:1 516:1
1 	|BT| (NP (NP (NP (NN Incubation) (NN CRC) (NN cell) (NN miR-221) (NN miR-222) (NN inhibitor)) (SBAR (S (NP (VBD reduced) (NN proliferation) (NN colony) (NN formation)) (VP (VBN compared) (NP (NN control) (NN cell))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 109:I01.696.116|ES| 19:1 43:1 50:1 94:1 140:1 141:1 245:1 289:1 299:1 314:1 380:1 452:1 517:1
1 	|BT| (NP (NP (ADVP (RB Interestingly)) (, ,) (NP (NP (NP (JJ gastric) (NN adenocarcinoma)) (ADJP (RB significantly) (JJ frequent)) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NP (NP (NN Cdh1) (-LRB- -LRB-) (NN F) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (NN Pdx-1-Cre)) (: ;) (NP (NN Smad4) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Trp53) (-LRB- -LRB-) (NN F/F) (-RRB- -RRB-)) (: ;) (NP (NN Cdh1) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-)) (NN mouse)) (, ,) (S (NP (VBG demonstrating) (NN Cdh1) (NN heterozygosity)) (VP (VBZ accelerates) (NP (NN development) (NN progression) (JJ gastric) (NN adenocarcinoma)))) (, ,) (NP (NN combination) (NN loss) (NN Smad4) (NN p53))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 70:A03.556.875.875 84:C04.557.470.200.025 118:D01.248.497.158.380 157:G05.380.383|ES| 2:1 10:1 12:1 14:1 19:1 32:1 35:1 48:1 51:1 52:1 86:1 124:1 217:1 255:1 518:1 519:1 520:1 521:1 522:1 523:1 524:1 525:1 526:1 527:1 528:1 529:1 530:1
1 	|BT| (S (NP (JJ Intestinal) (NN metaplasia) (NN dysplasia) (JJ low) (NN expression) (NN CDX2)) (VP (MD may) (VP (VB serve) (NP (JJ predictive) (NN marker) (JJ gastric) (NN cancer))))) |ET| |BS|47:A03.556.124 48:C23.550.589 158:D23.101|ES| 18:1 19:1 86:1 110:1 114:1 115:1 203:1 204:1 491:1 531:1 532:1 533:1 534:1
1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (NP (NP (NP (NP (JJ Triple) (JJ negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN TNBC)) (-RRB- -RRB-))) (NP (JJ aggressive) (ADJP (RB currently) (JJ specific)) (JJ therapeutic) (NN target))) (, ,) (NP (NP (NN hormone) (NN receptor) (JJ human) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN type) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN HER2)) (-RRB- -RRB-)))) (: ;) (ADVP (RB therefore)) (, ,) (NP (NN prognosis) (JJ poor))) |ET| |BS|52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 160:C04.588.180.788 161:D06.472 162:F01.145.126.125 163:E01.789|ES| 2:1 10:1 14:1 18:1 19:1 23:1 36:1 102:1 104:1 148:1 160:1 184:1 185:1 186:1 188:1 217:1 218:1 449:1 535:1 536:1 537:1 538:1 539:1 540:1 541:1 542:1 543:1 544:1 545:1
1 	|BT| (S (NP (NN K-Ras) (NN mutation) (NN treatment) (NN outcome) (JJ colorectal) (NN cancer) (NN patient)) (VP (VBG receiving) (NP (JJ exclusive) (NN fluoropyrimidine) (NN therapy)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 50:M01.643 52:E02 164:E01.789.800|ES| 13:1 17:1 18:1 19:1 34:1 120:1 130:1 546:1 547:1 548:1 549:1 550:1
1 	|BT| (S (NP (NN LINE-1) (NN methylation)) (VP (VBD decreased) (SBAR (S (NP (NN transition) (JJ intestinal) (NN metaplasia) (JJ gastric) (NN adenoma) (NN decrease)) (VP (VBD occurred) (NP (NN transition) (JJ gastric) (NN adenoma) (NN GC))))))) |ET| |BS|17:C04.557.470.035 36:G02.111.087.029.538 47:A03.556.124 48:C23.550.589 70:A03.556.875.875|ES| 19:1 42:1 81:1 86:1 109:1 110:1 202:1 295:1 551:1 552:1 553:1 554:1
1 	|BT| (S (NP (NP (ADJP (RB Little) (VBN known)) (JJ biological) (NN significance) (NN ELK1)) (, ,) (NP (JJ transcriptional) (NN factor))) (VP (VBZ activates) (NP (NP (JJ downstream) (NN target)) (PP (VBG including) (NP (NP (NN c-fos) (NN proto-oncogene)) (, ,) (NP (NN bladder) (NN cancer))))))) |ET| |BS|165:G05.360.340.024.340.375.500.791.330 166:D12.776.930 167:H01.158.273|ES| 2:1 18:1 19:1 160:1 185:1 301:1 440:1 555:1 556:1 557:1 558:1 559:1 560:1 561:1 562:1 563:1 564:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (NP (NP (NP (NN CRC) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN HCT116) (NN RKO)) (-RRB- -RRB-))) (VP (VBN transfected) (S (NP (NN miR-221) (NN miR-222)) (VP (VBP mimic) (NP (NN inhibitor))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 94:A11.251.210 168:E05.581|ES| 10:1 14:1 19:1 94:1 104:1 140:1 141:1 245:1 264:1 320:1 380:1 479:1 565:1 566:1 567:1
1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (NN Notch) (NN status)) (VP (VBD analysed) (S (VP (VBG studying) (S (NP (NN expression) (NN Notch) (NN effector) (NN Hes1) (NN Notch) (NNS ligands/receptors)) (NP (JJ human) (JJ colorectal) (NP (NP (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN mouse) (NN model) (NN Apc) (NN mutation)))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 169:D12.776.543.750.725 170:D27.720.470.480|ES| 10:1 14:1 17:1 18:1 19:1 34:1 36:1 52:1 72:1 104:1 115:1 245:1 256:1 258:1 280:1 416:1 565:1 568:1 569:1 570:1 571:1
1 	|BT| (NP (NP (NN Methylation) (NN rate) (NN SPARC) (NN gene)) (NP (NP (CD 80) (NN %)) (NP (CD ten) (JJ gastric) (NN cancer) (NN cell) (NN line)) (NP (NP (CD 74) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 163) (CD 220)) (-RRB- -RRB-))) (NP (JJ primary) (NN tumor))) (, ,) (NP (NP (ADJP (CD 5) (NN %)) (JJ normal) (JJ gastric) (NN mucosa)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 40)))) (-RRB- -RRB-)))) |ET| |BS|8:C04 36:G02.111.087.029.538 37:D12.776.157.125.715 94:A11.251.210 171:E05.318.308.985.775.500 172:A03.556.875.875.440 173:C07.465.864.500|ES| 2:1 7:1 9:1 10:1 14:1 18:1 19:1 41:1 82:1 86:1 94:1 118:1 264:1 344:1 369:1 572:1 573:1 574:1 575:1 576:1 577:1 578:1 579:1 580:1 581:1 582:1
1 	|BT| (FRAG (NP (S (NP (NP (NNS Mice) (NN mutation) (NN mismatch) (NN repair) (NN gene)) (, ,) (NP (NN Msh2) (NN Mlh1)) (, ,)) (VP (VBP exhibit) (S (NP (NN mismatch) (NN repair) (NN defect)) (VP (VBN predisposed) (S (VP (VBG developing) (NP (JJ gastrointestinal) (NN cancer)))))))) (, ,) (NN lymphoma) (NN tumor) (NN organ) (NN system))) |ET| |BS|6:G05.360.340.024.340 8:C04 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 174:G02.111.087.219.220 175:J01.897.280.500.269 176:C04.557.386|ES| 2:1 7:1 9:1 18:1 19:1 34:1 183:1 513:1 583:1 584:1 585:1 586:1 587:1 588:1 589:1 590:1 591:1 592:1 593:1
1 	|BT| (S (S (NP (NN miR-137) (NN overexpression)) (VP (VBD resulted) (NP (NP (NN downregulation) (NN CAR) (NN protein) (NN mRNA)) (PRN (-LRB- -LRB-) (PP (IN via) (NP (NN mRNA) (NN degradation))) (-RRB- -RRB-))))) (: ;) (S (VBN sensitized) (NP (JJ doxorubicin-resistant) (NN cell) (NN doxorubicin)) (-LRB- -LRB-) (VP (VP (VBN shown) (S (VP (VBN reduced) (NP (NN proliferation))))) (, ,) (VP (VBD increased) (NP (NN apoptosis))) (VP (VBD increased) (NP (JJ G2-phase) (NN cell) (NN cycle) (NN arrest))) (SINV (-RRB- -RRB-) (NP (VBD reduced) (FW vivo) (NN growth) (NN rate) (NN neuroblastoma) (NN xenograft)))))) |ET| |BS|7:D12.776 39:G04.299.139.160 41:A11 45:G07.700.320.249 85:G02.111.087.225 92:E04.936.764 93:A01.941.875 111:D13.444.735.544 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 139:J01.937.500.100 177:G04.299.134.109.500 178:G02.111.780|ES| 2:1 4:1 10:1 14:1 19:1 41:1 47:1 89:1 94:1 102:1 152:1 217:1 237:1 265:1 299:1 325:1 378:1 420:1 421:1 423:1 424:1 452:1 594:1 595:1 596:1 597:1 598:1 599:1 600:1 601:1 602:1
1 	|BT| (S (NP (NN miR-137)) (VP (VBZ regulates) (SBAR (S (NP (JJ constitutive) (NN androstane) (NN receptor)) (VP (VBZ modulates) (NP (NN doxorubicin) (NN sensitivity) (JJ parental) (JJ doxorubicin-resistant) (NN neuroblastoma) (NN cell))))))) |ET| |BS|41:A11 136:D02.455.426.559.847.562.050.200.175 137:C04.557.465.625.600.590.650.550 138:F01.829.263.500.320|ES| 19:1 94:1 186:1 420:1 422:1 423:1 424:1 599:1 603:1 604:1 605:1 606:1 607:1
1 	|BT| (S (NP (NN miR-490-3p)) (VP (VBD exhibited) (NP (NP (JJ progressive) (NN downregulation) (NN gastritis)) (, ,) (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN adenocarcinoma) (NN H))))) |ET| |BS|47:A03.556.124 48:C23.550.589 84:C04.557.470.200.025 85:G02.111.087.225 175:J01.897.280.500.269 179:D01.248.497.300.459.700 180:C06.405.205.697|ES| 2:1 19:1 109:1 110:1 255:1 595:1 608:1 609:1 610:1 611:1 612:1
1 	|BT| (S (NP (NN Mir-660)) (VP (VBD downregulated) (SBAR (S (NP (NN lung) (NN cancer) (NN patient) (NN replacement)) (VP (VBZ inhibits) (NP (NP (NN lung) (NN tumorigenesis)) (VP (VBG targeting) (NP (NN MDM2-p53) (NN interaction))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 50:M01.643 122:C14.280.383 181:E04.936.494 182:A04.411|ES| 18:1 19:1 78:1 120:1 328:1 426:1 613:1 614:1 615:1 616:1 617:1 618:1
1 	|BT| (S (NP (NP (NN miRNA-141)) (, ,) (VP (VBD downregulated) (NP (JJ pancreatic) (NN cancer))) (, ,)) (VP (VBZ inhibits) (NP (NN cell) (NN proliferation) (NN invasion)) (S (VP (ADVP (RB directly)) (VBG targeting) (NP (NN MAP4K4)))))) |ET| |BS|122:C14.280.383 183:G04.299.233.750 184:D13.150.650.319|ES| 2:1 18:1 19:1 94:1 299:1 426:1 465:1 467:1 615:1 616:1 619:1 620:1 621:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (VP (VBD identified) (SBAR (S (NP (NN Usp28) (NN c-MYC) (NN target) (NN gene)) (ADVP (RB highly)) (VBD expressed) (NP (JJ murine) (JJ human) (JJ intestinal) (NN cancer)) (, ,) (VP (VBZ indicates) (SBAR (S (NP (NN USP28) (NN c-MYC) (NN form) (JJ positive) (NN feedback) (NN loop)) (VP (VBZ maintains) (NP (JJ high) (NN c-MYC) (NN protein) (NN level) (NN tumor)))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 83:L01.143.283.425 101:C04.588.274.476.411 185:G05.360.340.024.340.375.500.791.420 186:G05.360.340.024.340.375.500.791.420 187:D08.622.705 188:N02.628 189:V02.460|ES| 2:1 4:1 6:1 7:1 9:1 18:1 19:1 36:1 109:1 160:1 178:1 233:1 247:1 248:1 249:1 622:1 623:1 624:1 625:1 626:1 627:1 628:1 629:1 630:1 631:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (JJ gastric) (NN cancer) (JJ human)) (ADVP (RB often)) (VP (VBD preceded) (NP (NP (JJ intestinal) (NN metaplasia)) (, ,) (NP (NN phenotype))) (S (VP (VBD described) (SBAR (S (ADVP (RB strongly)) (VP (VBZ suggests) (NP (NP (NN involvement) (NN Cdx2) (NN initiation) (NN process)) (VBG leading) (JJ intestinal) (NN neoplasia) (JJ gastric) (NN mucosa))))))))) |ET| |BS|47:A03.556.124 48:C23.550.589 55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 86:D01.268.556.435 190:C04.588.274.476.767 191:A03.556.124.369|ES| 2:1 18:1 19:1 36:1 86:1 109:1 110:1 213:1 236:1 331:1 579:1 622:1 632:1 633:1 634:1 635:1 636:1 637:1 638:1 639:1 640:1
1 	|BT| (S (ADVP (RB Moreover)) (, ,) (NP (NN CDX2) (NN expression)) (ADVP (RB progressively)) (VP (VBD reduced) (NP (JJ gastric) (NN dysplasia) (NN cancer)))) |ET| |BS|70:A03.556.875.875|ES| 2:1 18:1 19:1 86:1 114:1 115:1 201:1 203:1 452:1 622:1
1 	|BT| (S (NP (NP (NN Mutation) (NN Pla2g2a)) (, ,) (NP (JJ secretory) (NN phospholipase) (NN A) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (NP (NN gene)) (, ,)) (VP (VP (ADVP (RB dramatically)) (VB increase) (NP (NN number) (JJ intestinal) (NN polyp)) (VP (VB develop) (NP (NP (NP (JJ multiple) (JJ intestinal) (NN neoplasia)) (PRN (-LRB- -LRB-) (NP (NN Min)) (-RRB- -RRB-))) (NN mouse)))) (, ,) (NP (JJ murine) (ADJP (NN model) (JJ adenomatous) (NN polyposis) (NN coli) (JJ human))))) |ET| |BS|3:C04.557.470.035.215.100 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411 192:D08.811.277.352.100.680.750.937.750 193:C23.300.825.411|ES| 2:1 9:1 10:1 14:1 19:1 36:1 40:1 52:1 57:1 58:1 59:1 69:1 72:1 109:1 148:1 627:1 640:1 641:1 642:1 643:1 644:1 645:1 646:1 647:1 648:1 649:1 650:1
1 	|BT| (S (NP (NN Notch1)) (ADVP (RB directly)) (VP (VBD induced) (NP (NN CD133) (NN expression) (JJ human) (JJ diffuse) (NN type) (JJ gastric) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 36:1 86:1 115:1 412:1 543:1 621:1 651:1 652:1 653:1
1 	|BT| (S (NP (NP (CD One) (JJ common) (JJ rate-limiting) (NN mutation)) (JJ human) (NN CRC)) (VP (VBZ occurs) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 21:G05.360.340.024.340.375.249.050 55:B01.050.150.900.649.801.400.112.400.400 194:G05.355.044.250.750|ES| 9:1 10:1 11:1 14:1 19:1 34:1 36:1 57:1 58:1 59:1 245:1 654:1 655:1 656:1 657:1
1 	|BT| (S (NP (PRP$ Our) (NP (NP (JJ recent) (JJ global) (NN analysis) (NN CpG) (NN island) (NN hypermethylation) (NN gene) (NN expression) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD revealed) (S (NP (NN SOX17) (NN gene) (NN silencing)) (NP (VBN associated) (NN DNA) (NN hypermethylation) (NN CpG) (NN island) (NN promoter) (NN region))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 42:G05.355.315.203.374 94:A11.251.210 155:G05.355.310 195:G02.111.570.080.380.160 196:G02.111.570.080.689.675 197:A01.456.505.420 198:D13.444.308|ES| 9:1 10:1 14:1 17:1 18:1 19:1 83:1 94:1 100:1 115:1 169:1 245:1 264:1 275:1 658:1 659:1 660:1 661:1 662:1 663:1 664:1 665:1 666:1 667:1
1 	|BT| (NP (NP (NP (NN Overexpression) (NN miR-141) (JJ pancreatic) (NN cancer) (NN cell)) (VBD inhibited) (NP (NN cell) (NN proliferation)) (, ,) (NP (NP (NN clonogenicity)) (, ,) (NP (NN invasion)) (: ;) (NP (VBN induced) (NN G1) (NN arrest) (NN apoptosis)) (: ;) (NP (VBN enhanced) (NN chemosensitivity))))) |ET| |BS|39:G04.299.139.160 41:A11 122:C14.280.383 183:G04.299.233.750|ES| 2:1 18:1 19:1 89:1 94:1 217:1 299:1 365:1 385:1 386:1 412:1 463:1 467:1 602:1 620:1 668:1 669:1 670:1
1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1
1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1
1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1
1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1
1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1
1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1
1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1
1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1
1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
-1 	|BT| (S (NP (JJ Genetic) (NN analysis) (NN C/EBPalpha) (NN gene) (NN progress)) (VP (ADVP (RB fully)) (VB evaluate) (NP (ADJP (NN role) (JJ novel)) (NN tumor) (NN suppressor) (NN lung) (NN cancer)))) |ET| |BS|15:F01.829.316.616 206:G05.360.340.024.340.375.249 225:E05.337 259:D12.776.395.240.150.500 260:E01.370.225.562|ES| 7:1 9:1 18:1 19:1 31:1 328:1 661:1 700:1 886:1 887:1 888:1 889:1 890:1 891:1
-1 	|BT| (S (NP (JJ Preneoplastic) (JJ neoplastic) (NNS hepatocytes)) (VP (VBP undergo) (NP (NN c-Myc) (NN up-regulation) (NN overgrowth) (NN rat)) (NP (NP (RB genetically) (JJ susceptible) (NN hepatocarcinogenesis)) (, ,) (NP (JJ resistant) (NN rat))))) |ET| |BS|8:C04 142:I01.880.604 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 261:C23.550.291.687.500 262:A11.436.348|ES| 2:1 19:1 427:1 824:1 849:1 892:1 893:1 894:1 895:1 896:1 897:1 898:1 899:1 900:1
-1 	|BT| (NP (NP (NP (DT The) (NN HER2/neu) (NN oncogene) (JJ important) (JJ diagnostic) (JJ prognostic) (NN factor)) (NP (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|9:G05.360.340.024.340.375.500 10:A01.236 52:E02 63:G05.360.340.024.340.375.500.791.295.305 263:E01|ES| 18:1 19:1 23:1 24:1 160:1 185:1 541:1 691:1 884:1 901:1 902:1 903:1
-1 	|BT| (S (NP (DT A) (JJR better) (NN understanding) (NN mechanism) (NN Cby) (NN gene) (NN activation) (NN LSCC)) (VP (MD could) (VP (VB provide) (NP (JJ potential) (JJ novel) (JJ therapeutic) (NN target) (JJ human) (JJ laryngeal) (NN carcinoma))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 239:F02.463.188.357 259:D12.776.395.240.150.500 264:G05.355.315.800 265:C04.557.470.200 266:E07.695.450 267:A04.329|ES| 9:1 19:1 36:1 69:1 160:1 162:1 225:1 304:1 541:1 711:1 827:1 891:1 904:1 905:1 906:1 907:1 908:1 909:1
-1 	|BT| (S (NP (NP (DT A) (JJ functional) (JJ genomic) (NN approach)) (VP (VBG integrating) (NP (NP (NN microarray) (JJ proteomic) (NN analysis)) (VP (VBN done) (NP (NN laboratory)))))) (VP (VBD identified) (NP (JJ 14-3-3zeta) (JJ putative) (NN oncogene)) (WHNP (WHNP (WP$ whose) (NN activation)) (NP (JJ common) (VBN driven) (JJ genomic) (NN amplification) (NN lung) (NN adenocarcinoma))))) |ET| |BS|9:G05.360.340.024.340.375.500 66:F01.658.293 268:H01.158.273.180.350 269:G05.360.340 270:H01.158.201.843 271:N02.278.487|ES| 19:1 24:1 69:1 225:1 255:1 328:1 415:1 623:1 655:1 661:1 910:1 911:1 912:1 913:1 914:1 915:1 916:1 917:1 918:1 919:1 920:1 921:1
-1 	|BT| (S (NP (DT A) (NN relationship) (JJ renal) (NN tumor) (NN ASPS)) (ADVP (RB initially)) (VP (VBD suggested) (NP (JJ cytogenetic) (NN finding) (JJ balanced) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;)) (NP (CD q25)) (-RRB- -RRB-) (SBAR (S (NP (NP (CD two) (NN case)) (, ,) (NP (NN ASPL-TFE3) (NN fusion) (NN transcript))) (VP (VBD confirmed) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction))))))) |ET| |BS|272:E05.393.620.500.725 273:H01.158.273.343.180 274:C04.588.945.947.535 275:C23.888|ES| 2:1 7:1 10:1 14:1 19:1 69:1 217:1 223:1 768:1 922:1 923:1 924:1 925:1 926:1 927:1 928:1 929:1 930:1 931:1 932:1 933:1 934:1 935:1 936:1 937:1 938:1 939:1 940:1 941:1
-1 	|BT| (NP (NNS Aberrations) (NP (NP (NP (JJ fragile) (NN histidine) (NN triad)) (PRN (-LRB- -LRB-) (NP (NN FHIT)) (-RRB- -RRB-))) (NN gene) (JJ idiopathic) (JJ pulmonary) (NN fibrosis))) |ET| |BS|6:G05.360.340.024.340 276:C08.381.483.487.500 277:D12.125.072.329|ES| 9:1 10:1 14:1 19:1 942:1 943:1 944:1 945:1 946:1 947:1 948:1 949:1
-1 	|BT| (S (NP (VBG Activating) (NP (NN alteration) (NN variety) (JJ potential) (JJ oncogenic) (NN driver) (NN gene))) (ADVP (RB also)) (VP (VBD identified) (NP (NP (NNP NSCLC)) (, ,) (PP (VBG including) (NP (NN ROS1))) (, ,) (NP (NNP RET)) (, ,) (NP (NN MET)) (, ,) (NP (NN HER2)) (, ,) (NP (NN BRAF))))) |ET| |BS|18:G05.365.590 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 279:D27.888.569.100|ES| 2:1 5:1 9:1 19:1 188:1 329:1 561:1 623:1 827:1 950:1 951:1 952:1 953:1 954:1 955:1 956:1 957:1 958:1
-1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NN status) (NP (NP (JJ clinical) (NN significance) (JJ anaplastic) (NN lymphoma) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ALK)) (-RRB- -RRB-))) (NN gene) (NP (NP (NN alteration) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 104:C04.557.470.200.025.255|ES| 9:1 10:1 14:1 19:1 84:1 104:1 120:1 303:1 304:1 416:1 441:1 470:1 557:1 591:1 828:1 951:1 959:1 960:1 961:1 962:1
-1 	|BT| (NP (NP (NN ALK) (NN gene) (NN copy) (NN number)) (NP (NN gain) (JJ clinical) (NN significance) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 280:G05.380.350|ES| 9:1 19:1 84:1 303:1 304:1 557:1 646:1 962:1 963:1 964:1
-1 	|BT| (S (NP (DT All) (NN fusion)) (VP (VBD identified) (SBAR (S (NP (NP (NNP RET) (NN KIF5B) (NN gene)) (, ,) (NP (NP (NNP RET) (NN fusion) (NN CCDC6) (NN NCOA4) (NN gene)) (, ,) (NP (JJ characteristic) (NN thyroid) (NN cancer)) (, ,))) (VP (VBD identified) (NP (JJ irradiated) (NN lung) (NN cell))))))) |ET| |BS|6:G05.360.340.024.340 13:D01.339.387 41:A11 182:A04.411 281:E02.815|ES| 2:1 9:1 18:1 19:1 94:1 328:1 336:1 623:1 936:1 956:1 965:1 966:1 967:1 968:1 969:1 970:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 36:1 48:1 98:1 115:1 217:1 245:1 556:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1
-1 	|BT| (NP (NP (NP (NP (JJ Altered) (NN expression) (JJ human) (NN enhancer) (NN filamentation) (CD 1)) (PRN (-LRB- -LRB-) (NP (NP (NN HEF1)) (: ;) (NP (ADJP (RB also) (VBN known)) (NN NEDD9) (NN Cas-L))) (-RRB- -RRB-))) (NP (VBN implicated) (NN progression) (NN melanoma) (, ,) (NN breast) (, ,) (NN CRC)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 10:A01.236 15:F01.829.316.616 16:C23.550.291.656 32:C04.697.098.500 33:C04.697.098 55:B01.050.150.900.649.801.400.112.400.400 142:I01.880.604 239:F02.463.188.357 282:C04.557.465.625.650.510|ES| 2:1 5:1 10:1 14:1 19:1 23:1 31:1 36:1 48:1 78:1 98:1 115:1 217:1 245:1 433:1 438:1 556:1 889:1 971:1 972:1 973:1 974:1 975:1 976:1 977:1 978:1 979:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NP (NP (JJ additional) (NN study) (NN animal) (NN model)) (VP (VBN needed) (, ,))) (VP (VBG finding) (VP (VBP suggest) (S (VP (VBG targeting) (NP (NN HMGA2))))))) (VP (MD could) (SBAR (S (NP (RB therapeutically) (JJ beneficial) (NN lung) (NN cancer) (NN cancer)) (VP (VBD characterized) (NP (VBN increased) (NN HMGA2) (NN expression))))))))) |ET| |BS|283:D12.776.260.312.937 284:N03.349.380.420 285:E05.598|ES| 2:1 18:1 19:1 46:1 47:1 72:1 107:1 115:1 131:1 328:1 616:1 796:1 908:1 927:1 980:1 981:1 982:1 983:1 984:1 985:1
-1 	|BT| (FRAG (SBAR (IN Although) (S (NP (NN CTCF)) (VP (VBD described) (NP (NP (NP (ADJP (RB significantly) (VBN mutated)) (NN gene) (JJ endometrial) (NN cancer) (NN TCGA)) (, ,) (NP (NN A) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NN track))) (SBAR (S (NP (JJ variant) (VBG leading) (NN T204) (NNS frameshifts)) (VP (VBD reported))))))))) |ET| |BS|6:G05.360.340.024.340 86:D01.268.556.435 286:C04.588.945.418.948.585 287:G05.365.590.265|ES| 2:1 9:1 10:1 14:1 18:1 19:1 69:1 107:1 124:1 229:1 276:1 634:1 639:1 986:1 987:1 988:1 989:1 990:1 991:1 992:1 993:1
-1 	|BT| (S (SBAR (IN Although) (S (NP (NP (NN therapy)) (VP (VBG targeting) (NP (JJ high) (NN EphA1) (NN expression)))) (VP (VBP seem) (NP (JJ plausible) (NN CRC))))) (, ,) (S (NP (NN loss) (NN expression)) (VP (VBD advanced) (NP (NN disease)))) (VP (VBZ suggests) (SBAR (S (NP (NP (NP (JJ potential) (NN risk)) (VBN targeted) (NN therapy)) (, ,) (VP (VBG selecting) (NP (NN loss) (NN expression))) (, ,)) (VP (MD might) (VP (VB contribute) (NP (NN disease) (NN progression)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 16:C23.550.291.656 38:Z01.058.290.120.180 40:Z01.542.248.700 52:E02 61:E05.318.740.600.800 288:C23.550.288|ES| 2:1 16:1 19:1 32:1 48:1 107:1 115:1 130:1 171:1 178:1 245:1 331:1 450:1 616:1 798:1 827:1 994:1 995:1 996:1 997:1 998:1 999:1
-1 	|BT| (S (PP (IN Among) (NP (ADJP (RB frequently) (VBN deleted)) (JJ chromosomal) (NN site))) (, ,) (NP (NN LOH) (NN chromosome) (NN 3p)) (VP (VBD detected) (NP (NN MM)) (, ,) (S (VP (VBG suggesting) (S (NP (NN presence)) (NP (CD one) (NP (JJ several) (NN tumour) (NN suppressor) (NN gene) (JJ important) (NN role)) (NN development) (NN disease))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 206:G05.360.340.024.340.375.249 289:A11.284.187 290:G05.365.590.029.530 291:F03.625.421|ES| 2:1 9:1 19:1 31:1 35:1 262:1 346:1 698:1 700:1 902:1 998:1 1000:1 1001:1 1002:1 1003:1 1004:1 1005:1 1006:1 1007:1 1008:1 1009:1 1010:1 1011:1
-1 	|BT| (S (NP (NN Amplification) (NN over-expression) (NN MAP3K3) (NN gene) (JJ human) (NN breast) (NN cancer)) (VP (VBZ promotes) (NP (NN formation) (NN survival) (NN breast) (NN cancer) (NN cell)))) |ET| |BS|20:G03.495 55:B01.050.150.900.649.801.400.112.400.400 108:G04.299.316 155:G05.355.310|ES| 9:1 18:1 19:1 23:1 36:1 43:1 94:1 274:1 298:1 1012:1 1013:1 1014:1
-1 	|BT| (S (NP (DT An) (JJ integrative) (NN bioinformatics) (NN analysis) (NN region)) (VP (VBN nominated) (NP (NN MAP3K3) (NN gene) (JJ potential) (JJ therapeutic) (NN target) (NN breast) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 9:G05.360.340.024.340.375.500 10:A01.236 12:Z01.542.049 52:E02 240:H01.158.273.180 292:Z01|ES| 9:1 18:1 19:1 23:1 160:1 541:1 661:1 667:1 827:1 830:1 1014:1 1015:1 1016:1 1017:1
-1 	|BT| (S (NP (NN Analysis) (NN TP53) (NN CTNNB1) (NN gene) (NN mutation)) (NP (NNP HG) (NN component) (NNS MASCs)) (ADVP (RB well)) (NP (NN detection) (NN copy) (NN number) (NN aberration) (NN EGFR) (NN CCND1) (NN gene)) (VP (VBP harbor) (NP (NN abnormality)))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 23:D12.776.091.249 254:C16.131 293:D01.268.556.504 294:G05.360.340.024.340.137|ES| 9:1 19:1 34:1 119:1 187:1 646:1 787:1 963:1 1018:1 1019:1 1020:1 1021:1 1022:1 1023:1 1024:1 1025:1 1026:1 1027:1
-1 	|BT| (NP (NP (PP (IN As) (NP (NN result))) (, ,) (NP (NP (NN CDCA1) (JJ novel) (NN cancer-testis) (NN antigen) (JJ overexpressed) (NN LC)) (, ,) (NP (JJ cholangiocellular) (NN cancer)) (, ,) (NP (JJ urinary) (NN bladder) (NN cancer) (JJ renal) (NN cell) (NN cancer)) (, ,) (NP (NN CDCA1)) (VP (MD may) (ADVP (RB therefore)) (NP (JJ ideal) (NN TAA) (JJ useful) (NN diagnosis) (NN immunotherapy) (NN cancer)))))) |ET| |BS|259:D12.776.395.240.150.500 263:E01 295:C04.557.470.200.025.390 296:D02.065.064.786 297:C14.907.055.239.125 298:E02.095.465.425 299:D23.050|ES| 2:1 18:1 19:1 25:1 94:1 101:1 168:1 218:1 491:1 564:1 891:1 922:1 1028:1 1029:1 1030:1 1031:1 1032:1 1033:1 1034:1 1035:1 1036:1 1037:1 1038:1
-1 	|BT| (S (PP (IN As) (NP (NP (NN Bim) (NN expression) (JJ critical) (NN biomarker) (NN response)) (NP (JJ many) (VBN targeted) (NN therapy)))) (, ,) (NP (NN PTK6) (NN inhibition)) (VP (MD may) (VP (VB offer) (NP (NP (JJ therapeutic) (NN approach)) (VP (VBG treating) (NP (NN patient) (NN Her2) (VBN targeted) (JJ therapy-resistant) (NN breast) (NN cancer))))))) |ET| |BS|43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101|ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1
-1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NN MUC4) (VBN cloned) (JJ tracheobronchial) (NN mucosa) (NN cDNA)) (ADVP (RB reportedly)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NP (JJ human) (NN malignancy)) (, ,) (PP (VBG including) (NP (NN lung) (NN carcinoma)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 182:A04.411 265:C04.557.470.200 300:D13.444.308.497.220 301:A11.251.353 302:A10.615.550|ES| 2:1 6:1 19:1 36:1 49:1 104:1 304:1 328:1 561:1 579:1 626:1 1046:1 1047:1 1048:1 1049:1 1050:1 1051:1
-1 	|BT| (NP (NP (NP (JJ Basal) (NN cell) (NN carcinosarcoma) (NN PTCH1) (NN mutation)) (NP (JJ epithelial) (JJ sarcomatoid) (JJ primary) (NN tumor) (NN component) (JJ sarcomatoid) (NN metastasis)))) |ET| |BS|8:C04 18:G05.365.590 41:A11 113:C04.697.650 303:C04.557.450.795 304:C04.557.435.290|ES| 7:1 19:1 34:1 94:1 127:1 344:1 806:1 1021:1 1052:1 1053:1 1054:1 1055:1
-1 	|BT| (S (VP (JJ BCL2-like) (NP (NP (CD 11) (NN intron) (CD 2) (NN deletion) (NN polymorphism)) (VP (VBN associated) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN risk) (NN prognosis)))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 61:E05.318.740.600.800 110:C04.588.894.797.520.109.220.249 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 18:1 19:1 94:1 148:1 169:1 171:1 328:1 544:1 694:1 1056:1 1057:1 1058:1 1059:1 1060:1
-1 	|BT| (S (NP (NN CD133)) (VP (VBN considered) (S (NP (NP (JJ stem-like) (NN cell) (NN marker) (NN cancer)) (PP (VBG including) (NP (NP (JJ gastric) (NN cancer)) (, ,) (NP (NP (NN Notch1) (NN signaling)) (VP (VBN known) (NP (NN play) (JJ important) (NN role) (NN maintenance) (NN differentiation) (JJ stem-like) (NN cell)))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 74:G04.299.151 79:I03.450.642.693 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937|ES| 2:1 18:1 19:1 31:1 86:1 94:1 195:1 215:1 238:1 534:1 556:1 561:1 651:1 652:1 902:1 1061:1 1062:1 1063:1
-1 	|BT| (NP (NP (NN Characterization) (JJ tumor-suppressive) (NN function) (NN SOX6) (JJ human) (NN esophageal) (JJ squamous) (NN cell) (NN carcinoma))) |ET| |BS|8:C04 55:B01.050.150.900.649.801.400.112.400.400|ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1
-1 	|BT| (S (NP (NN Chemokine) (NN gene) (NN expression) (JJ clonal) (NN analysis) (NN B) (NN cell) (NN tissue)) (VP (VBN involved) (NP (JJ lymphoid) (JJ interstitial) (NN pneumonitis) (JJ HIV-infected) (JJ pediatric) (NN patient)))) |ET| |BS|50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670|ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1
-1 	|BT| (S (NP (JJ Chromosomal) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ close) (JJ genetic) (NN relationship) (NN papillary) (JJ urothelial) (JJ choriocarcinomatous) (NN tumor) (NN component)) (, ,) (VP (VBG documenting) (NP (JJ first) (NN time) (NN choriocarcinoma) (JJ renal) (NN pelvis)))) (VP (VBP result) (NP (JJ clonal) (NN evolution) (JJ urothelial) (NN carcinoma) (NN acquisition) (JJ trophoblastic) (NN differentiation))))))) |ET| |BS|8:C04 74:G04.299.151 149:G05.360.340.024.340.364.875.890 289:A11.284.187 316:C04.557.465.955.207 317:C04.557.470.200.430 318:A05.810.453.537 319:A11.382.992 320:G04.299.350 321:A10.272.850 322:G01.910|ES| 2:1 7:1 19:1 101:1 215:1 223:1 275:1 304:1 661:1 816:1 864:1 922:1 1021:1 1069:1 1075:1 1076:1 1077:1 1078:1 1079:1 1080:1 1081:1 1082:1 1083:1 1084:1 1085:1 1086:1
-1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
-1 	|BT| (S (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root)))) (NP (VBD suggested) (NN B))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 272:1 412:1 534:1 661:1 763:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1
-1 	|BT| (S (NP (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root))))))) (VP (VBD suggested) (SBAR (S (NP (NNP B.) (JJ thuringiensis-induced) (NN defense) (NN system)) (VP (VBD activated) (NP (NP (NN leaf)) (, ,) (NP (NN stem)) (, ,) (NP (JJ main) (NN root) (NN tissue)) (, ,) (NP (JJ lateral) (NN root) (NN tissue)))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 309:A18.024.937 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650 329:A14.549.167.900.750 330:A18.024.812|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 163:1 272:1 412:1 534:1 593:1 661:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1 1102:1 1103:1 1104:1 1105:1 1106:1 1107:1 1108:1
-1 	|BT| (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (VP (NN DCAMKL-1) (NP (JJ negative) (NN regulator) (NN let-7a) (NN miRNA) (NN biogenesis) (JJ intestinal) (NN stem) (JJ colorectal) (NN cancer) (NN cell)))) (: ;)) (VP (MD could) (VP (VB represent) (NP (JJ novel) (NN target) (JJ anti-cancer) (NN stem) (JJ cell-based) (NN strategy))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 47:A03.556.124 184:D13.150.650.319 259:D12.776.395.240.150.500 309:A18.024.937 331:G16.595 332:A11.872.650 333:D01.045|ES| 17:1 18:1 19:1 94:1 104:1 109:1 160:1 217:1 235:1 239:1 449:1 799:1 840:1 891:1 908:1 1106:1 1109:1 1110:1 1111:1 1112:1 1113:1 1114:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Expression) (NN ra) (NN protein) (NN type) (CD II) (JJ alveolar) (NNS pneumocytes) (NN mutation) (NN codon) (CD 12) (JJ K-ras) (NN gene) (NN lung) (NN tissue)) (VP (MD may) (VP (VB contribute) (NP (NN induction) (NN lung) (NN carcinoma) (NN patient) (NN IPF)))))) |ET| |BS|18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765|ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (NN Jab1) (NN expression)) (, ,) (NP (ADVP (RB well)) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN upregulation)) (, ,) (NP (JJ evident) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN Jab1)) (VP (MD could) (NP (JJ diagnostic) (NN marker) (NN treatment) (NN target) (JJ precancerous) (NN lesion) (JJ early) (NNS HCCs))))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 158:D23.101 249:G05.355.315.800 263:E01 338:D12.644.360.225.600 339:G02.111.087.880 340:C17.800.229.400 341:C04.834|ES| 2:1 10:1 14:1 19:1 104:1 115:1 160:1 239:1 534:1 546:1 787:1 900:1 903:1 908:1 1009:1 1123:1 1124:1 1125:1 1126:1 1127:1 1128:1 1129:1 1130:1 1131:1 1132:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Reduction) (NN ING1b) (NN gene) (NN expression)) (VP (VBN associated) (VP (VBD reduced) (NP (NN p21) (NN bax) (NN gene) (NN expression) (NNS NSCLCs)))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400|ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (CD two) (NN library)) (ADVP (RB differentially)) (VP (VBD expressed) (SBAR (S (NP (NN gene)) (VP (MD may) (VP (VB provide) (NP (NN basis) (JJ new) (NN insight) (NN clue) (NN finding) (JJ novel) (NN lung) (JJ cancer-related) (NN gene)))))))) (: ;) (S (NP (JJ several) (NN gene)) (ADVP (RB newly)) (VP (VBD found) (NP (NP (NN lung) (NN cancer) (NN ERGIC3)) (VP (VBG seeming) (NP (JJ novel) (NN lung) (JJ cancer-related) (NN gene))))))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438|ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (DT This) (NN panel)) (SBAR (S (NP (JJ variant-specific) (, ,) (JJ quantitative) (NN RT-PCR) (NN assay)) (VP (VBZ detects) (NP (NP (JJ common) (NN EML4-ALK) (CC +) (JJ variant) (RB well) (NN ALK) (NN gene) (NN expression) (NN level)) (JJ archival) (JJ formalin-fixed) (JJ paraffin-embedded) (NN NSCLC) (NN specimen))))))) |ET| |BS|106:E05.091 110:C04.588.894.797.520.109.220.249 155:G05.355.310 272:E05.393.620.500.725 345:E01.370.225.500.620.720.610 346:E05.393.620.500.706 347:D02.047.407 348:K01.400.152|ES| 2:1 9:1 19:1 104:1 115:1 239:1 249:1 310:1 329:1 510:1 655:1 787:1 807:1 817:1 962:1 990:1 1147:1 1148:1 1149:1 1150:1 1151:1 1152:1 1153:1 1154:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (PRP We)) (VP (VBD provided) (NP (JJ first) (NN evidence) (NN SOX6) (JJ novel) (JJ tumor-suppressor) (NN gene) (NN ESCC) (NN development) (JJ potential) (JJ prognostic) (NN marker) (NN ESCC)))) |ET| |BS|149:G05.360.340.024.340.364.875.890 158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 19:1 35:1 38:1 104:1 239:1 534:1 816:1 827:1 843:1 884:1 891:1 1065:1 1155:1 1156:1 1157:1
-1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
-1 	|BT| (S (NP (NP (NP (NN DDR2)) (PRN (-LRB- -LRB-) (NP (NN L63V)) (-RRB- -RRB-))) (: ;) (NP (NP (NN TP53)) (PRN (-LRB- -LRB-) (NP (NN L/L)) (-RRB- -RRB-))) (NP (NN mouse))) (VP (VBD developed) (NP (NP (ADJP (RB poorly) (VBN differentiated)) (NN lung) (NN adenocarcinoma) (JJ transgenic) (NN animal)) (VP (VBN analyzed) (NP (NN latency) (CD 40) (CD 50) (NN week) (NN median) (NN survival) (CD 67.5) (NN week)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 74:G04.299.151 96:I03.784 352:B01.050.050.136|ES| 10:1 14:1 19:1 46:1 52:1 217:1 255:1 274:1 285:1 328:1 368:1 582:1 783:1 1018:1 1162:1 1163:1 1164:1 1165:1 1166:1 1167:1 1168:1 1169:1 1170:1 1171:1
-1 	|BT| (S (NP (NN DEP) (NN domain)) (VP (VP (VBG containing) (NP (CD 1) (-LRB- -LRB-) (NN DEPDC1) (-RRB- -RRB-))) (SBAR (S (NP (ADJP (RB newly) (VBN identified)) (NP (JJ cancer-related) (NN cell) (NN cycle)) (JJ related) (NN gene)) (VP (VBD demonstrated) (NP (JJ novel) (JJ therapeutic) (NN target) (NN bladder) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 259:D12.776.395.240.150.500 353:G04.299.134|ES| 9:1 10:1 14:1 18:1 19:1 94:1 98:1 160:1 286:1 419:1 541:1 564:1 601:1 623:1 891:1 1143:1 1144:1 1172:1 1173:1 1174:1 1175:1
-1 	|BT| (S (NP (NN DEPDC1)) (VP (VBD required) (NP (NN cell) (NN cycle) (NN progression) (NN motility) (JJ nasopharyngeal) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 353:G04.299.134|ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN BCL6B)) (VP (MD may) (VP (VB serve) (NP (JJ independent) (NN biomarker) (NN prognosis) (NN GC))))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 491:1 532:1 544:1 554:1 883:1 885:1 1179:1 1180:1 1181:1
-1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN PAX5)) (VP (VBD utilized) (NP (JJ independent) (JJ prognostic) (NN factor) (NN GC)))))) |ET| |BS|36:G02.111.087.029.538 243:D12.776.260.645.500|ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1
-1 	|BT| (S (NP (NP (NN Detection)) (VP (VBN methylated) (NP (NN TBX5)))) (VP (MD may) (VP (VB serve) (NP (JJ potential) (NN biomarker) (NN prognosis) (NN malignancy))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 49:1 491:1 532:1 544:1 827:1 885:1 1179:1 1180:1 1183:1
-1 	|BT| (S (NP (NN Detection) (NN TFPI2) (NN methylation) (NN stool) (NN DNA)) (VP (MD may) (VP (VB act) (NP (JJ useful) (NN adjunct) (JJ noninvasive) (NN strategy) (NN screening) (NNS CRCs) (NN future))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 81:E02.095.465.425.400.330.050.400 198:D13.444.308 354:I01.320 355:A12.459|ES| 19:1 81:1 246:1 491:1 666:1 1036:1 1114:1 1179:1 1184:1 1185:1 1186:1 1187:1 1188:1 1189:1 1190:1
-1 	|BT| (NP (NP (NP (NN DLGAP5) (NN overexpression) (JJ evident) (CD 25) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD 22) (CD 88))) (-RRB- -RRB-))) (NP (NP (NNP HCC) (NN specimen)) (PP (IN without) (NP (NN AFP) (NN expression)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN DLGAP5)) (VP (MD may) (NP (JJ novel) (NN biomarker) (NN HCC) (NN pathogenesis)))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 115:1 152:1 369:1 441:1 491:1 501:1 885:1 891:1 1009:1 1127:1 1154:1 1191:1 1192:1 1193:1 1194:1 1195:1 1196:1
-1 	|BT| (NP (NP (JJ Dual) (JJ therapeutic) (NN effect) (NN interferon-alpha) (NN gene) (NN therapy) (NN rat) (JJ hepatocellular) (NN carcinoma) (NN model) (NN liver) (NN cirrhosis))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 356:D12.644.276.374.440.890.250 357:C06.552.630|ES| 9:1 19:1 72:1 75:1 130:1 303:1 304:1 541:1 836:1 849:1 1197:1 1198:1 1199:1
-1 	|BT| (NP (NP (NN EGFR) (NN gene) (NN mutation) (NN ALK) (NN gene) (NN fusion) (JJ well-characterized) (JJ molecular) (NN target) (NN NSCLC))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 358:G05.360.340.024.340.375.500.791.295.300 359:G05.355.760.385|ES| 9:1 19:1 34:1 160:1 161:1 187:1 329:1 936:1 962:1 1200:1
-1 	|BT| (NP (NP (JJ Epigenetic) (NN dysregulation) (JJ leukaemic) (NN HOX) (NN code) (JJ MLL-rearranged) (NN leukaemia) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 360:N04.452.758.708.200.400.500 361:C04.557.337|ES| 19:1 52:1 72:1 1201:1 1202:1 1203:1 1204:1 1205:1 1206:1 1207:1
-1 	|BT| (S (NP (NN Evaluation) (NN RB) (NN status)) (VP (MD may) (NP (JJ useful) (JJ prognostic) (NN factor) (JJ human) (NN HCC)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 225:E05.337|ES| 19:1 36:1 185:1 416:1 441:1 491:1 884:1 1036:1 1208:1 1209:1
-1 	|BT| (S (NP (NN Expression) (NN DRD2)) (VP (VBZ Is) (SBAR (S (NP (VBN Increased) (JJ Human) (JJ Pancreatic) (JJ Ductal) (NN Adenocarcinoma) (NNS Inhibitors)) (VP (VBP Slow) (NP (NN Tumor) (NN Growth) (NNS Mice))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 362:D12.776.543.750.069.300.400.500 363:C04.557.470.200.025.232.750 364:D27.505.696.377.450|ES| 19:1 316:1 444:1 583:1 1210:1 1211:1 1212:1 1213:1 1214:1 1215:1 1216:1 1217:1 1218:1 1219:1
-1 	|BT| (S (NP (NP (NP (CD Fifty-four)) (PRN (-LRB- -LRB-) (NP (CD 73) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 74) (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient) (NN lung) (NN carcinoma) (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 46) (NN sample)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient)) (PP (IN without) (NP (NN lung) (NN carcinoma))))))))) (VP (VBD showed) (NP (NP (NNP LOH) (NNP FHIT) (NN gene)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.0001)))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1
-1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN CD133) (NN DNA) (NN methylation)) (VP (VBZ seems) (VP (VBP constitute) (SBAR (S (NP (JJ abnormal) (NN promoter) (NN signature)) (VP (VBD found) (NP (NP (JJ normal) (NN brain) (NN colon)) (VP (VBN cultured) (NP (JJ primary) (NN tumor)))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 366:G02.111.087.029.538.161 367:A08.186.211|ES| 2:1 7:1 19:1 37:1 81:1 83:1 113:1 118:1 334:1 344:1 652:1 666:1 1227:1 1228:1 1229:1 1230:1 1231:1 1232:1
-1 	|BT| (S (NP (NNP Gene) (NN amplification) (NN 17q) (JJ chromosomal) (NN region)) (VP (VBN observed) (ADVP (RB frequently)) (NP (NN breast) (NN cancer)))) |ET| |BS|292:Z01 368:C23.550.210.182|ES| 18:1 19:1 23:1 261:1 667:1 698:1 921:1 1002:1 1233:1 1234:1
-1 	|BT| (S (NP (JJ Genomic) (NN Sequencing)) (VP (VBZ Identifies) (NP (NN ELF3) (NN Driver) (NNP Ampullary) (NNP Carcinoma)))) |ET| |BS|265:C04.557.470.200 268:H01.158.273.180.350 269:G05.360.340|ES| 19:1 1235:1 1236:1 1237:1 1238:1 1239:1 1240:1 1241:1
-1 	|BT| (S (NP (NN HEF1)) (VP (MD may) (VP (VB represent) (NP (NP (JJ attractive) (NN candidate) (NN drug)) (VP (VBG targeting) (NP (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 369:E02.319.300|ES| 19:1 191:1 245:1 491:1 616:1 799:1 974:1 1242:1 1243:1
-1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NN prevalence) (NN pattern) (NN mutation)) (NP (NP (CD two) (NN gene)) (, ,) (NP (NN Ha-ras) (NN beta-catenin)) (, ,)) (VP (VBN known) (NP (JJ mutational) (NN target) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 60:E05.318.308.985.525.750 216:Z01.107.084.900.425|ES| 2:1 9:1 19:1 34:1 52:1 60:1 160:1 179:1 260:1 400:1 403:1 556:1 747:1 900:1 933:1 1244:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (VBD generated) (NN mouse) (NN model) (NN lung) (NN adenocarcinoma)) (VP (VBN driven) (NP (NP (NN mutation) (NN discoidin) (NN domain) (NN receptor) (CD 2) (-LRB- -LRB-) (NN DDR2) (-RRB- -RRB-) (NN gene)) (JJ combined) (NN loss) (NN TP53)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 66:F01.658.293|ES| 2:1 9:1 10:1 14:1 19:1 32:1 34:1 52:1 72:1 73:1 148:1 164:1 186:1 255:1 328:1 400:1 920:1 1018:1 1162:1 1173:1 1245:1
-1 	|BT| (S (NP (JJR Higher) (NN frequency) (JJ inactive) (NN TP53) (NN mutation)) (ADVP (RB also)) (VP (VBN seen) (S (NP (NP (NP (JJ advanced) (NN stage) (NN tumour)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0003)))) (-RRB- -RRB-))) (NN tumour) (JJ poor) (JJ prognostic) (NN feature)) (NP (ADJP (NP (JJ vascular)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.006)))) (-RRB- -RRB-))) (NP (NP (JJ lymphatic) (NN invasion)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 159:I01.880.735.634 194:G05.355.044.250.750 213:F02.830.816.964 370:A15.382.520.301 371:A07.231|ES| 5:1 10:1 14:1 19:1 34:1 311:1 545:1 581:1 620:1 724:1 884:1 997:1 1011:1 1018:1 1129:1 1246:1 1247:1 1248:1 1249:1 1250:1 1251:1 1252:1 1253:1 1254:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NN mutation) (NN exon) (CD 3) (NN beta-catenin) (NN gene)) (VP (VBD detected) (SBAR (S (NP (CD one) (NN tumour)) (VP (VBD expressed) (NP (JJ nuclear) (NN beta-catenin) (JJ lining) (JJ polygonal) (NN component))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 372:G05.360.340.024.340.137.232|ES| 2:1 6:1 9:1 19:1 34:1 60:1 433:1 862:1 1007:1 1010:1 1011:1 1021:1 1255:1 1256:1 1257:1 1258:1
-1 	|BT| (S (NP (NN HOX) (NN gene)) (ADVP (RB frequently)) (VP (VBN dysregulated) (NP (NP (JJ human) (NN leukaemia) (NN gene) (NN rearrangement) (JJ mixed) (NN lineage) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN MLL)) (-RRB- -RRB-))) (NP (NN partner) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330|ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1
-1 	|BT| (NP (NP (NP (NN Identification) (NN trophinin) (NN enhancer) (NN cell) (NN invasion) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer))) |ET| |BS|41:A11 374:F01.393.446 375:Z01.639.100|ES| 18:1 19:1 94:1 185:1 328:1 620:1 884:1 972:1 1128:1 1129:1 1265:1 1266:1
-1 	|BT| (S (NP (NN IHH) (NN SMO)) (VP (MD may) (SBAR (S (NP (JJ useful) (NNS biomarkers) (JJ diffuse) (NN cancer)) (VP (MD may) (VP (VB show) (NP (NN growth) (NN inhibition) (NN Hh) (NN antagonist) (NN cyclopamine)))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 376:D23.101.140|ES| 18:1 19:1 102:1 103:1 429:1 491:1 653:1 1036:1 1267:1 1268:1 1269:1 1270:1 1271:1 1272:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ CF-treated) (JJ main) (NN root))) (, ,) (NP (NP (JJ CF-treated) (JJ lateral) (NN root)) (, ,) (NP (NP (NN expression) (JJ several) (JJ salicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (: -) (S (NP (JJ responsive) (JJ defense-related) (NN gene)) (ADVP (RB specifically)) (VP (VBD induced) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (JJ jasmonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN JA)) (-RRB- -RRB-))) (: -) (NP (JJ related) (NN gene) (NN expression))) (VP (CC either) (VP (VBD down-regulated) (NP (JJ induced) (NN response) (NN CF)))))))))) |ET| |BS|52:E02 142:I01.880.604 155:G05.355.310 325:Z01.058.290.100.140 326:A18.400 351:A17.360 377:D02.241.223.100.300.595.608|ES| 2:1 9:1 10:1 14:1 19:1 39:1 115:1 244:1 262:1 372:1 412:1 494:1 1100:1 1101:1 1107:1 1108:1 1273:1 1274:1 1275:1 1276:1 1277:1 1278:1 1279:1 1280:1 1281:1 1282:1 1283:1
-1 	|BT| (FRAG (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (VBN defined) (NN subset) (NN bone) (JJ soft) (NN tissue) (NN tumor)) (, ,) (PP (VBG including) (NP (JJ benign) (NN tumor))) (, ,) (S (NP (NN Akt)) (ADVP (RB frequently)) (VP (VBN overexpressed) (S (VP (VBN activated))))) (, ,) (NP (NP (NNP AKT1/2) (NN copy) (NN number)) (VP (VBN increased))))) |ET| |BS|378:D08.811.913.696.620.682.700.755 379:C04.588.839 380:A02.835.232 381:C04|ES| 2:1 7:1 19:1 25:1 47:1 163:1 244:1 272:1 561:1 646:1 680:1 698:1 963:1 1284:1 1285:1 1286:1 1287:1 1288:1 1289:1 1290:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN change) (NN level) (NN cdk4)) (VP (MD may) (NP (JJ useful) (NN biomarker) (NN detection) (NN HCC))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101|ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN WT1)) (VP (VBD expressed) (NP (NP (JJ substantial) (NN proportion) (NN HCC)) (VP (VBG contributing) (NP (NN tumor) (NN progression) (NN resistance) (NN chemotherapy)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN WT1)) (VP (MD may) (NP (JJ important) (NN target) (NN HCC) (NN treatment))))))))) |ET| |BS|8:C04 12:Z01.542.049 16:C23.550.291.656 52:E02 104:C04.557.470.200.025.255 151:E02.319 382:C04.557.435.595|ES| 2:1 6:1 7:1 19:1 48:1 160:1 244:1 441:1 491:1 495:1 546:1 902:1 1009:1 1094:1 1284:1 1292:1 1293:1 1294:1 1295:1
-1 	|BT| (S (PP (IN In) (NP (NN silico) (NN analysis))) (VP (VBD used) (SBAR (S (NP (NN probe) (NN association) (NN gene) (NN expression) (NN signature) (NN RB) (NN loss) (JJ chromosomal) (NN instability) (NN ability) (NN gene)) (VP (VBD up-regulated) (SBAR (S (NP (NN RB) (NN loss)) (VP (VBP predict) (NP (NN survival) (JJ human) (NN HCC) (NN patient)))))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 96:I03.784 104:C04.557.470.200.025.255 142:I01.880.604 150:Z01.542.248.960 383:C23.550.210.110 384:G02.111.087.847.750 385:F02.784.629.131 386:F02.463.425.069 387:L01.224.160|ES| 9:1 19:1 32:1 36:1 115:1 120:1 244:1 274:1 441:1 476:1 661:1 1002:1 1209:1 1230:1 1296:1 1297:1 1298:1 1299:1 1300:1 1301:1 1302:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD found) (S (S (NP (NN EREG) (JJ overexpressed) (NNS NSCLCs)) (VP (VBG harboring) (NP (NNP KRAS)))) (, ,) (NP (NNP BRAF) (NN EGFR) (NN mutation)) (VP (VBN compared) (NP (NNS NSCLCs) (JJ wild-type) (NN KRAS/BRAF/EGFR)))))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 388:G05.360.340.024.340.375.500.791.550|ES| 2:1 8:1 19:1 25:1 34:1 37:1 50:1 131:1 175:1 187:1 244:1 958:1 1137:1 1303:1 1304:1 1305:1 1306:1
-1 	|BT| (UCP (PP (IN In) (NP (JJ present) (NN study) (JJ novel) (JJ metastasis-related) (NN gene))) (, ,) (NP (NP (NP (JJ eukaryotic) (NN initiation) (NN factor) (NN 5A2)) (PRN (-LRB- -LRB-) (NP (NN EIF5A2)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN characterized) (NN role) (NN HCC) (NN metastasis)) (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 259:D12.776.395.240.150.500 389:D12.776.835.725.868|ES| 2:1 9:1 10:1 14:1 19:1 31:1 131:1 161:1 162:1 185:1 244:1 435:1 441:1 637:1 806:1 891:1 985:1 1307:1 1308:1 1309:1 1310:1 1311:1
-1 	|BT| (NP (NP (NP (VBN Increased) (NN loss) (NN chromosome) (NN 9p21) (NN p16) (NN inactivation)) (NP (JJ primary) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN smoker)))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 289:A11.284.187|ES| 18:1 19:1 32:1 94:1 328:1 344:1 694:1 1005:1 1212:1 1312:1 1313:1 1314:1 1315:1
-1 	|BT| (S (NP (NN ING5)) (VP (VP (VBZ suppresses) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN migration) (NN invasion)))) (, ,) (VP (VBZ induces) (NP (JJ autophagy) (NN differentiation) (JJ gastric) (NN cancer) (NN cell))) (: :) (NP (JJ good) (NN marker) (NN carcinogenesis) (JJ subsequent) (NN progression)))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 39:G04.299.139.160 74:G04.299.151 158:D23.101 390:G04.299.139.399|ES| 2:1 18:1 19:1 48:1 86:1 89:1 94:1 104:1 207:1 214:1 215:1 299:1 514:1 534:1 620:1 686:1 1316:1 1317:1 1318:1 1319:1
-1 	|BT| (NP (NP (JJ Irrespective) (NN protein) (NN overexpression)) (, ,) (S (NP (NN HER-2)) (: /) (NP (NP (NN neu) (NN gene) (NN amplification) (JJ rare) (NN lung) (NN cancer) (NN study) (NN prevalence) (JJ clinicopathological) (NN implication) (JJ early) (NN stage) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NCSLC)) (-RRB- -RRB-))) (NP (NP (JJ neuroendocrine) (NN tumour)) (PRN (-LRB- -LRB-) (NP (NN NET)) (-RRB- -RRB-))) (VP (NN lung) (S (VP (VBG lacking)))))) |ET| |BS|7:D12.776 63:G05.360.340.024.340.375.500.791.295.305 110:C04.588.894.797.520.109.220.249 237:C04.588.894.797.520 391:E05.318.760.500.875 392:G05.355.315.250 393:A06.688|ES| 2:1 4:1 9:1 10:1 14:1 18:1 19:1 85:1 94:1 131:1 152:1 179:1 328:1 376:1 694:1 921:1 1011:1 1128:1 1129:1 1320:1 1321:1 1322:1 1323:1 1324:1 1325:1 1326:1
-1 	|BT| (S (NP (PRP It)) (ADJP (ADJP (RB likely) (JJ major)) (SBAR (S (NP (NN genotype) (JJ gastric) (NN carcinoma)) (VP (VBD placed) (NP (JJS least) (CD 4) (NN microsatellite) (NN category)) (, ,) (S (ADVP (RB thus)) (VP (VBG allowing) (NP (NP (NN construction) (JJ comprehensive) (JJ genetic) (NN classification)) (JJ useful) (NN prediction) (JJ diverse) (JJ clinical) (NN course))))))))) |ET| |BS|70:A03.556.875.875 265:C04.557.470.200 394:G02.111.570.080.708.800.500 395:L01.100 396:G05.380|ES| 2:1 19:1 84:1 86:1 304:1 319:1 462:1 864:1 1036:1 1327:1 1328:1 1329:1 1330:1 1331:1 1332:1 1333:1 1334:1 1335:1 1336:1 1337:1 1338:1 1339:1 1340:1 1341:1
-1 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN expression)) (VP (MD might) (VP (VP (VBN employed) (S (NP (JJ good) (NN marker) (JJ gastric) (NN carcinogenesis) (JJ subsequent) (NN progression)) (VP (VBG inhibiting) (NP (NN proliferation))))) (, ,) (NP (NP (NN growth)) (, ,) (NP (NN migration)) (, ,) (NP (NN invasion) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 45:G07.700.320.249 70:A03.556.875.875 113:C04.697.650 122:C14.280.383 158:D23.101|ES| 2:1 19:1 48:1 86:1 102:1 115:1 207:1 299:1 514:1 534:1 620:1 798:1 806:1 880:1 925:1 1316:1 1318:1 1319:1 1327:1 1342:1
-1 	|BT| (S (NP (JJ Knock-down) (NN Prmt1) (JJ insufficient) (JJ reverse) (JJ active) (NN chromatin) (NN status)) (VP (VBN hypomethylated) (NP (NN Hox) (NN locus)) (, ,) (S (VP (VBG suggesting) (S (NP (JJ Prmt1-mediated) (NN histone) (NN arginine) (NN methylation)) (VP (ADVP (RB partially)) (NP (VBN involved) (NP (NN maintenance) (NN Hox) (NN expression) (JJ leukaemic) (NN cell))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 188:N02.628 351:A17.360 397:A11.284.430.106.279.345.190.160.180 398:D12.125.068.050 399:D12.776.660.470|ES| 2:1 19:1 81:1 94:1 115:1 197:1 377:1 416:1 503:1 774:1 939:1 1009:1 1063:1 1203:1 1343:1 1344:1 1345:1 1346:1 1347:1 1348:1 1349:1 1350:1 1351:1
-1 	|BT| (S (NP (JJ Knock-down) (NN TnC) (NN gene)) (VP (VBD increased) (NP (NN susceptibility) (JJ DSS-induced) (NN colitis)) (, ,) (S (VP (VBN compared) (S (NP (NP (NN TnC)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NNS littermates))))))) |ET| |BS|53:C06.405.205.265 400:E05.393.335.500 401:C23.550.291.687|ES| 2:1 9:1 10:1 14:1 19:1 47:1 50:1 51:1 143:1 1343:1 1352:1 1353:1 1354:1 1355:1
-1 	|BT| (NP (NP (S (NP (JJ K-ras) (NN gene) (NN mutation)) (VP (VBZ enhances) (NP (NN motility) (VBN immortalized) (NN airway) (NN cell) (NN lung) (NN adenocarcinoma) (NN cell)) (PP (IN via) (NP (NN Akt) (NN activation)))) (: :)) (NP (JJ possible) (NN contribution) (JJ non-invasive) (NN expansion) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 41:A11 378:D08.811.913.696.620.682.700.755|ES| 9:1 19:1 34:1 94:1 104:1 225:1 255:1 328:1 596:1 1121:1 1177:1 1289:1 1356:1 1357:1 1358:1 1359:1 1360:1 1361:1 1362:1
-1 	|BT| (S (NP (NNP KRAS) (NN gene) (NN mutation)) (VP (VBN linked) (NP (NP (JJ poor) (NN prognosis) (NN resistance)) (JJ therapeutic) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|18:G05.365.590 52:E02 110:C04.588.894.797.520.109.220.249 159:I01.880.735.634 163:E01.789|ES| 9:1 10:1 14:1 18:1 19:1 34:1 94:1 328:1 329:1 541:1 544:1 545:1 694:1 1094:1 1305:1 1363:1
-1 	|BT| (NP (NP (NP (JJ K-ras) (NN gene) (JJ mutational) (NN analysis)) (NN support) (JJ monoclonal) (NN origin) (JJ biphasic) (JJ pleomorphic) (NN carcinoma) (NN lung))) |ET| |BS|18:G05.365.590 149:G05.360.340.024.340.364.875.890 182:A04.411 265:C04.557.470.200|ES| 9:1 19:1 304:1 328:1 661:1 1121:1 1244:1 1364:1 1365:1 1366:1 1367:1 1368:1
-1 	|BT| (NP (NP (NP (NP (NNP KRAS) (NN mutation) (CD one) (JJ common) (NN driver) (NN mutation) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (SBAR (S (NP (NN finding) (JJ druggable) (NN target) (NN molecule)) (VP (VBP inhibit) (NP (JJ oncogenic) (NNP KRAS) (NN signaling) (JJ significant) (NN challenge) (NN NSCLC) (NN therapy))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 69:G02.111.087.800 110:C04.588.894.797.520.109.220.249 122:C14.280.383 275:C23.888 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 10:1 14:1 18:1 19:1 34:1 130:1 135:1 160:1 180:1 195:1 327:1 328:1 329:1 655:1 927:1 953:1 954:1 1010:1 1305:1 1369:1 1370:1 1371:1
-1 	|BT| (S (NP (NNP LOH) (NNP FHIT) (NN locus)) (ADVP (RB frequently)) (VP (VBN found) (PP (IN among) (NP (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium) (NN patient) (NN IPF))) (PRN (-LRB- -LSB-) (NP (NP (CD 62) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (NP (CD 119) (JJ informative) (NN lesion))) (-RRB- -RSB-)))) |ET| |BS|48:C23.550.589 50:M01.643 62:A10.272 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 10:1 14:1 19:1 37:1 120:1 173:1 369:1 377:1 698:1 946:1 1004:1 1122:1 1131:1 1222:1 1223:1 1372:1 1373:1 1374:1 1375:1 1376:1 1377:1 1378:1
-1 	|BT| (NP (NP (JJ Mammary) (NN analogue) (JJ secretory) (NN carcinoma) (JJ salivary) (NN gland) (JJ high-grade) (NN transformation)) (: :) (NP (NP (NN report) (ADJP (CD 3) (NN case)) (NN ETV6-NTRK3) (NN gene) (NN fusion) (NN analysis) (NN TP53)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NN EGFR)) (, ,) (NP (NN CCND1) (NN gene)))) |ET| |BS|23:D12.776.091.249 359:G05.355.760.385 402:G05.360.340.024.340.375.500.791.148 403:C04.557.470.200.588 404:A03.556.500.760 405:V03.100 406:V03.100|ES| 2:1 9:1 19:1 60:1 104:1 187:1 304:1 417:1 643:1 661:1 862:1 934:1 936:1 1018:1 1025:1 1379:1 1380:1 1381:1 1382:1 1383:1 1384:1 1385:1
-1 	|BT| (NP (NP (NP (JJ Mammary) (NN tumour)) (NP (VBN observed) (NN EphB4) (JJ transgenic) (NN animal))) (: ;) (NP (ADVP (RB however)) (, ,) (NP (NP (JJ double) (JJ transgenic) (NN animal) (VBG expressing) (NN EphB4) (NN neuT) (NN gene)) (, ,) (NP (NN tumour) (NN appearance)) (S (S (ADVP (RB significantly)) (VP (VBD accelerated))) (, ,) (NP (NP (NN contrast) (JJ neuT-only) (NN animal)) (, ,) (NP (NN metastasis)) (NP (VBD observed) (NN lung))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 19:B01.050 113:C04.697.650 182:A04.411 352:B01.050.050.136 407:E01.370.225.812.735.550 408:C04.588.531|ES| 2:1 9:1 19:1 46:1 124:1 217:1 261:1 285:1 328:1 806:1 810:1 1011:1 1379:1 1386:1 1387:1 1388:1 1389:1 1390:1 1391:1 1392:1 1393:1
-1 	|BT| (S (NP (JJ Maternal) (NN folate) (NN level) (NN polymorphism) (JJ folate-related) (NN gene)) (VP (VBN known) (NP (NP (NN risk) (NN factor) (JJ neural) (NN tube) (NN defect)) (PRN (-LRB- -LRB-) (NP (NNS NTDs)) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 224:D03.438.733.631.400 307:G05.365.795 409:E05.318.740.600.800.725 410:F01.829.263.500.320.200 411:C10.500.680|ES| 9:1 10:1 14:1 19:1 171:1 185:1 249:1 556:1 588:1 778:1 1060:1 1394:1 1395:1 1396:1 1397:1 1398:1
-1 	|BT| (S (NP (NNS METHODS) (: :)) (NP (NP (JJ Aberrant) (NN methylation) (NN status) (NN p16) (NN promoter) (NN region)) (, ,) (NP (NN expression) (NN product)) (, ,) (NP (NP (NN loss) (NN heterozygosity)) (PRN (-LRB- -LRB-) (NP (NN LOH)) (-RRB- -RRB-))) (NP (NN 9p21))) (VP (VBD examined) (NP (NP (NP (ADJP (RB surgically) (JJ resected)) (NN lung) (NN specimen) (CD 57) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 28) (JJ male) (CD 29) (NN female)) (-RRB- -RRB-))) (S (NP (JJ peripheral-type) (NN lung) (NN adenocarcinoma)) (VP (VBG measuring) (NP (ADVP (JJR <) (: /)) (NP (JJ =) (CD 2) (NN cm) (NN diameter)))))))) |ET| |BS|36:G02.111.087.029.538 50:M01.643 115:E04 168:E05.581 182:A04.411 196:G02.111.570.080.689.675 203:G05.360.340.024.340.375.249.375 228:E05.978 290:G05.365.590.029.530|ES| 2:1 10:1 14:1 19:1 32:1 80:1 81:1 83:1 104:1 115:1 120:1 148:1 255:1 312:1 324:1 326:1 328:1 416:1 528:1 565:1 667:1 675:1 1004:1 1154:1 1312:1 1313:1 1399:1 1400:1 1401:1 1402:1 1403:1 1404:1 1405:1 1406:1 1407:1 1408:1 1409:1
-1 	|BT| (NP (NP (NN Methylation) (NN TFPI2) (NN stool) (NN DNA)) (: :) (NP (JJ potential) (JJ novel) (NN biomarker) (NN detection) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 36:G02.111.087.029.538 158:D23.101 198:D13.444.308 259:D12.776.395.240.150.500 355:A12.459|ES| 17:1 18:1 19:1 104:1 572:1 666:1 827:1 885:1 891:1 1023:1 1184:1 1185:1
-1 	|BT| (S (NP (NNS Mutations) (NN EGFR) (NN gene)) (VP (VBD detected) (NP (NP (JJ pulmonary) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS ADCs)) (-RRB- -RRB-))))) |ET| |BS|18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 9:1 10:1 14:1 19:1 187:1 255:1 948:1 1007:1 1410:1 1411:1
-1 	|BT| (NP (NP (NNP New) (NN aspect) (JJ clinicopathologic) (NN oncogene) (NN study)) (NP (CD 23) (JJ pulmonary) (JJ lymphoepithelioma-like) (NN carcinoma))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 265:C04.557.470.200|ES| 19:1 24:1 131:1 304:1 948:1 1412:1 1413:1 1414:1 1415:1 1416:1
-1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NP (JJ brain-targeted) (NN gene) (NN therapy) (JJ recombinant) (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN rAAV5)) (-RRB- -RRB-))) (: -) (NP (NN IDUA) (NN vector) (NN MPS-I) (JJ transgenic) (NN mouse) (NN model))) (VP (MD would) (VP (VB reverse) (NP (JJ pathological) (NN hallmark))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 99:B01.050.050.136.500 367:A08.186.211 412:C16.320.565.202.715.640 413:B04.280.580.650.170 414:B04.280.580.650.170 415:F01.658.500 416:G05.360.337 417:H02.403.650|ES| 9:1 10:1 14:1 19:1 52:1 72:1 104:1 130:1 221:1 285:1 362:1 828:1 866:1 939:1 1417:1 1418:1 1419:1 1420:1 1421:1 1422:1 1423:1 1424:1 1425:1 1426:1 1427:1
-1 	|BT| (NP (NP (NP (JJ Odd-skipped) (JJ related) (CD 1) (JJ novel) (NN tumour) (NN suppressor) (NN gene)) (JJ potential) (JJ prognostic) (NN biomarker) (JJ gastric) (NN cancer))) |ET| |BS|158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 18:1 19:1 86:1 98:1 419:1 700:1 827:1 884:1 885:1 891:1 1011:1 1428:1
-1 	|BT| (S (PP (IN Of) (NP (JJ acidophilic) (NN lesion))) (PRN (, ,) (NP (NP (NP (NN majority) (NN focus)) (PRN (-LRB- -LRB-) (NP (NP (CD 28/32)) (, ,) (NP (CD 88) (NN %))) (-RRB- -RRB-))) (NN adenoma) (-LRB- -LRB-) (CD 47/50) (, ,) (NP (CD 94) (NN %))) (-RRB- -RRB-)) (VP (VBD expressed) (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (VP (VBN increased) (SBAR (S (NP (NN bcl-2)) (VP (VBN observed) (NP (NP (ADJP (CD 12.5) (NN %)) (JJ acidophilic) (JJ preneoplastic) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/32)) (-RRB- -RRB-))) (NP (NP (ADJP (CD 14) (NN %)) (JJ acidophilic) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 7/50)) (-RRB- -RRB-))))))))))) |ET| |BS|17:C04.557.470.035 54:G05.360.340.024.340.375.500.791.150 418:D12.644.360.075.718.937 419:C04.557.465.625.650.025|ES| 2:1 6:1 10:1 14:1 19:1 42:1 47:1 151:1 198:1 261:1 369:1 372:1 1131:1 1194:1 1429:1 1430:1 1431:1 1432:1 1433:1 1434:1 1435:1 1436:1 1437:1 1438:1 1439:1 1440:1 1441:1
-1 	|BT| (SINV (PP (IN Of) (NP (JJ small-cell) (JJ heterogeneous) (JJ basophilic) (NN lesion))) (, ,) (CD 86) (VP (NN %) (VP (NN focus) (SBAR (S (-LRB- -LRB-) (S (S (NP (NP (QP (CD 31/36) (-RRB- -RRB-) (CD 85) (NN %)) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 35/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (VBN increased) (NN bcl-2) (NN protein) (NN level)) (PP (VBN compared) (S (VP (VBG surrounding) (NP (JJ normal) (NNS hepatocytes)))))))) (, ,) (IN whereas) (S (NP (NP (NP (ADJP (CD 12.5) (NN %)) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/36)) (-RRB- -RRB-))) (ADJP (CD 12) (NN %)) (NN adenoma) (PRN (-LRB- -LRB-) (NP (CD 5/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (NN level)))))))))) |ET| |BS|7:D12.776 17:C04.557.470.035 41:A11 54:G05.360.340.024.340.375.500.791.150 175:J01.897.280.500.269 262:A11.436.348 418:D12.644.360.075.718.937 420:A11.118.637.415.120 421:G05.365.331 422:N01|ES| 2:1 4:1 10:1 14:1 19:1 42:1 47:1 50:1 118:1 151:1 249:1 369:1 372:1 609:1 894:1 1120:1 1131:1 1429:1 1431:1 1435:1 1436:1 1437:1 1442:1 1443:1 1444:1 1445:1 1446:1 1447:1 1448:1 1449:1 1450:1 1451:1
-1 	|BT| (S (ADVP (NP (CD One) (NN year)) (RB later)) (, ,) (NP (JJ intra-abdominal) (JJ metastatic) (NN tumor)) (VP (VBD detected) (ADJP (JJ resected)))) |ET| |BS|8:C04 9:G05.360.340.024.340.375.500 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 158:D23.101 198:D13.444.308 303:C04.557.450.795 372:G05.360.340.024.340.137.232 423:A01.923.047.025 424:L01.143.506.423.557 425:G01.358.500.505.650 426:E01.370.350.515 427:C04.588.033 428:D27.720.233|ES| 2:1 7:1 9:1 19:1 68:1 118:1 127:1 272:1 337:1 344:1 534:1 654:1 666:1 806:1 833:1 965:1 1007:1 1021:1 1055:1 1250:1 1255:1 1327:1 1400:1 1452:1 1453:1 1454:1 1455:1 1456:1 1457:1 1458:1 1459:1 1460:1 1461:1 1462:1 1463:1 1464:1 1465:1 1466:1 1467:1
-1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB firmly)) (VP (VBP establish) (NP (JJ unique) (JJ oncogenic) (NN capability) (NN DNp73) (NN drive)) (ADVP (FW hepatocarcinogenesis) (FW vivo)) (, ,) (S (VP (VBG supporting) (NP (NN significance) (NN marker) (NN disease) (NN severity) (NN patient) (NN target) (NN cancer) (NN prevention)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 66:F01.658.293 158:D23.101 279:D27.888.569.100 288:C23.550.288|ES| 2:1 18:1 19:1 120:1 160:1 181:1 220:1 378:1 534:1 557:1 658:1 793:1 900:1 953:1 998:1 1468:1 1469:1 1470:1 1471:1 1472:1 1473:1 1474:1
-1 	|BT| (NP (NP (PRP$ Our) (S (VP (NN finding) (VP (VB identify) (NP (NN EphA1) (JJ potential) (JJ prognostic) (NN marker) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 158:D23.101|ES| 19:1 245:1 534:1 658:1 827:1 832:1 884:1 927:1 994:1
-1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (JJ allelic) (NN loss) (NN FHIT) (NN gene)) (VP (MD may) (NP (VBN involved) (NN carcinogenesis) (JJ peripheral) (NN lung) (NN patient) (NN IPF))))))) |ET| |BS|6:G05.360.340.024.340 33:C04.697.098 50:M01.643 182:A04.411 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765|ES| 9:1 19:1 32:1 120:1 207:1 328:1 491:1 658:1 774:1 796:1 927:1 946:1 1122:1 1475:1 1476:1
-1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (NN KLLN)) (VP (MD might) (VP (VBN used) (NP (JJ potential) (JJ prognostic) (NN marker) (JJ novel) (NN therapy) (NN target) (NN breast) (NN carcinoma)))))))) |ET| |BS|52:E02 158:D23.101 259:D12.776.395.240.150.500 429:N04.761.559.590.900 430:E05.581.249|ES| 19:1 23:1 130:1 160:1 304:1 476:1 534:1 658:1 796:1 798:1 827:1 884:1 891:1 1477:1 1478:1
-1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (NP (S (NP (NN miR-9) (NN miR-197)) (VP (ADVP (RB specifically)) (VBP downregulate) (NP (NN MTHFD1L) (NN level) (NN HEK293) (NN MCF-7) (NN cell) (NN SNPrs7646)) (ADVP (RB significantly)) (VP (VBP affect) (NP (NP (NN miR-197) (NN binding) (NN affinity) (NN MTHFD1L) (CD 3)) ('' ') (NN UTR)) (, ,) (S (VP (VBG causing) (NP (NP (JJ efficient) (JJ posttranscriptional) (NN gene) (NN repression) (NN presence) (NN allele)) (VP (VBN associated)))))))) (NP (VBD increased) (NN risk) (NNS NTDs))))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 77:G05.360.340.024.340.030 208:F01.393.821 252:F02.784.692.351 411:C10.500.680 431:D13.444.735.544.875 432:A11.251.210.190.630 433:F01.470.047|ES| 2:1 9:1 19:1 47:1 94:1 101:1 124:1 169:1 171:1 230:1 249:1 346:1 508:1 658:1 706:1 862:1 1279:1 1398:1 1479:1 1480:1 1481:1 1482:1 1483:1 1484:1 1485:1 1486:1 1487:1 1488:1 1489:1 1490:1 1491:1 1492:1 1493:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (S (NP (NN offer) (JJ preclinical) (NN rationale)) (VP (VBG warranting) (NP (NP (JJ clinical) (NN investigation)) (VP (VBG combining) (NP (NNS HDACi) (NN EGFR) (JJ HER2-targeted) (NN therapy) (NN CRC) (NN treatment))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337|ES| 19:1 84:1 101:1 130:1 187:1 245:1 505:1 546:1 658:1 1042:1 1494:1 1495:1 1496:1 1497:1 1498:1 1499:1
-1 	|BT| (NP (NP (NN Overactivation) (NN Wnt-beta-catenin) (NN signaling)) (, ,) (PP (VBG including) (NP (NP (NN beta-catenin-TCF) (NN target) (NN gene) (NN expression)) (, ,) (NP (NP (NN hallmark) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 105:G02.149.115.800.925 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 35:1 115:1 160:1 195:1 245:1 561:1 1427:1 1500:1 1501:1 1502:1
-1 	|BT| (NP (NP (NN P53) (NN gene) (JJ deficient) (NN mouse)) (SBAR (-LRB- -LRB-) (S (S (NP (NN p53) (PRN (: -) (: /) (: -) (-RRB- -RRB-))) (VP (VBD found) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ malignant) (NN lymphoma) (NN hemangiosarcoma))))) (, ,) (IN whereas) (FRAG (NP (NN heterozygote)) (-LRB- -LRB-) (NP (NP (NP (NN p53)) (CC +) (: /) (: -) (-RRB- -RRB-) (NN mouse) (NN display) (JJ high) (NN incidence) (NN tumor) (JJ urinary) (NN bladder)) (VP (VBN treated) (NP (NN N-butyl-N) (: -) (-LRB- -LRB-) (NN 4-hydroxybutyl) (-RRB- -RRB-) (NN nitrosamine)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 157:G05.380.383 176:C04.557.386 434:E05.318.308.985.525.375 435:C04.557.450.795.390 436:C04.588.945.947.960 437:D02.654.442|ES| 2:1 7:1 9:1 10:1 14:1 19:1 37:1 52:1 178:1 372:1 564:1 591:1 648:1 802:1 1033:1 1099:1 1503:1 1504:1 1505:1 1506:1 1507:1 1508:1 1509:1 1510:1 1511:1 1512:1 1513:1 1514:1
-1 	|BT| (NP (NP (NN Pdcd4)) (S (-LRB- -LRB-) (NP (VBN programmed) (NP (NP (NN cell) (NN death) (CD 4) (-RRB- -RRB-) (NN gene)) (NN tumor) (NN suppressor) (NN expression))) (ADVP (RB frequently)) (VP (VBD down-regulated) (NP (NN tumor)) (, ,) (NP (NP (VBN considered) (JJ diagnostic) (JJ prognostic) (NN marker)) (NP (ADJP (RB well) (JJ promising)) (NN target) (JJ anti-cancer) (NN therapy)))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 52:E02 142:I01.880.604 158:D23.101 206:G05.360.340.024.340.375.249 263:E01 351:A17.360|ES| 2:1 7:1 9:1 10:1 14:1 19:1 94:1 115:1 130:1 160:1 319:1 411:1 534:1 698:1 700:1 787:1 884:1 903:1 1061:1 1112:1 1283:1 1515:1 1516:1 1517:1
-1 	|BT| (NP (NP (NP (NN Point) (NN mutation) (JJ K-ras) (NN gene)) (, ,) (VP (VBD found) (NP (NP (ADJP (QP (CD 10) (CD 30)) (NN %)) (NN lung) (NN adenocarcinoma)) (, ,) (NP (VBN regarded) (RB early) (NN event) (NN carcinogenesis)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 438:G05.365.590.675|ES| 2:1 9:1 19:1 34:1 37:1 205:1 207:1 255:1 328:1 369:1 1121:1 1128:1 1518:1 1519:1 1520:1 1521:1
-1 	|BT| (NP (NP (NP (JJ Primary) (JJ renal) (NN neoplasm) (NN ASPL-TFE3) (NN gene) (NN fusion) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (: :) (S (NP (JJ distinctive) (NN tumor) (NN entity)) (ADVP (RB previously)) (VP (VBD included) (PP (IN among) (NP (JJ renal) (NN cell) (NN carcinoma) (NN child))) (ADVP (JJ adolescent)))))) |ET| |BS|8:C04 274:C04.588.945.947.535 295:C04.557.470.200.025.390 359:G05.355.760.385 439:C04.557.450.590.775 440:M01.060.057 441:M01.060.406|ES| 7:1 9:1 19:1 94:1 104:1 304:1 451:1 922:1 935:1 936:1 1117:1 1287:1 1372:1 1522:1 1523:1 1524:1 1525:1 1526:1 1527:1 1528:1 1529:1 1530:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (VP (VBG Activating) (NP (NP (NP (NP (JJ somatic) (NN mutation) (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN gene)) (ADJP (ADJP (JJ present)) (ADJP (JJ small))) (NN subset) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 442:G05.360.340.024.340.375.500.791.295.300 443:G05.700.264|ES| 9:1 10:1 14:1 19:1 34:1 102:1 104:1 184:1 185:1 186:1 187:1 255:1 328:1 388:1 687:1 750:1 950:1 1285:1 1307:1
-1 	|BT| (S (NP (VBN Reduced) (NN ING1b) (NN gene) (NN expression)) (VP (VBP play) (NP (NP (JJ important) (NN role)) (NN carcinogenesis) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 50:M01.643 79:I03.450.642.693 110:C04.588.894.797.520.109.220.249 155:G05.355.310|ES| 9:1 18:1 19:1 31:1 94:1 115:1 120:1 207:1 238:1 328:1 694:1 902:1 1134:1 1531:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN EGFR) (NN gene) (NN mutation)) (VP (VBD identified) (NP (NP (CD 13) (NN %)) (NP (JJ primary) (NN tumor))))) |ET| |BS|8:C04 18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 7:1 9:1 19:1 34:1 104:1 187:1 344:1 369:1 623:1 710:1 1532:1
-1 	|BT| (S (NP (NN SMO)) (VP (MD might) (NP (NP (JJ good) (JJ therapeutic) (NN target) (NN patient)) (NP (JJ colorectal) (NN polyp) (NN carcinoma))) (, ,) (NP (RB even) (NN absence) (NN Hh) (NN signal) (NN activation)))) |ET| |BS|50:M01.643 52:E02 265:C04.557.470.200 444:C23.300.825|ES| 2:1 17:1 19:1 120:1 160:1 225:1 304:1 541:1 647:1 798:1 859:1 1268:1 1270:1 1318:1 1533:1 1534:1
-1 	|BT| (S (NP (NN SPOCK1) (NN act) (NN oncogene)) (VP (MD may) (NP (NP (JJ prognostic) (NN factor) (JJ therapeutic) (NN target) (NN patient)) (NP (NNP GBC))))) |ET| |BS|9:G05.360.340.024.340.375.500 50:M01.643 52:E02 81:E02.095.465.425.400.330.050.400|ES| 19:1 24:1 120:1 160:1 185:1 246:1 491:1 541:1 884:1 1535:1 1536:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN downregulation)) (VP (MD might) (VP (VBN involved) (SBAR (S (NP (NP (NN carcinogenesis)) (, ,) (NP (NN growth)) (, ,) (NP (NN invasion) (NN lung) (NN cancer))) (VP (MD could) (VP (VBN considered) (S (NP (JJ promising) (NN marker) (NN gauge) (NN aggressiveness) (NN lung) (NN cancer))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 45:G07.700.320.249 85:G02.111.087.225 158:D23.101 162:F01.145.126.125|ES| 2:1 18:1 19:1 102:1 207:1 328:1 534:1 595:1 620:1 774:1 793:1 798:1 908:1 925:1 1061:1 1316:1 1517:1 1537:1 1538:1 1539:1 1540:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBG finding) (SBAR (S (NP (JJ indicated) (NN PVT1/EZH2/LATS2) (NN interaction)) (VP (MD might) (VP (VB serve) (NP (JJ new) (NN target) (NN lung) (NN adenocarcinoma) (NN diagnosis) (NN therapy)))))))) |ET| |BS|52:E02 263:E01|ES| 2:1 19:1 130:1 160:1 255:1 328:1 532:1 618:1 712:1 798:1 927:1 1037:1 1537:1 1538:1 1541:1 1542:1
-1 	|BT| (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (JJ first) (NN time) (NN miR-372)) (VP (VBZ suppresses) (NP (NN tumorigenesis) (NN development) (NN EC))))))) (: ;) (FRAG (NP (NP (NN RhoC)) (JJ new) (ADJP (RB potentially) (JJ important)) (JJ therapeutic) (NN target)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 52:E02 322:G01.910|ES| 2:1 19:1 35:1 78:1 101:1 160:1 217:1 541:1 686:1 712:1 773:1 816:1 902:1 1081:1 1175:1 1537:1 1538:1 1543:1 1544:1 1545:1
-1 	|BT| (S (NP (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (JJ present) (NN work)) (VP (VBD revealed) (NP (JJ novel) (NN function) (NN TIP30)) (, ,) (VP (ADVP (RB possibly)) (VBN used) (S (NP (JJ independent) (ADJP (JJ prognostic) (NN factor) (JJ potential)) (JJ therapeutic) (NN target) (JJ gastric) (NN cancer)))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 445:I03.946|ES| 2:1 18:1 19:1 33:1 86:1 160:1 185:1 275:1 476:1 541:1 827:1 883:1 884:1 891:1 1307:1 1537:1 1538:1 1546:1 1547:1 1548:1
-1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN SRC-3)) (VP (MD may) (NP (JJ important) (NN oncogene) (JJ therapeutic) (NN target) (NN lung) (NN cancer))))))) |ET| |BS|9:G05.360.340.024.340.375.500 52:E02|ES| 2:1 18:1 19:1 24:1 160:1 328:1 491:1 541:1 793:1 796:1 902:1 1537:1 1538:1 1549:1
-1 	|BT| (S (NP (NNP TaqMan) (NN PCR) (NN genotyping) (NN technology)) (VP (VBD used) (VP (VB detect) (NP (NP (NP (NN genotype) (NN ITGA3) (NN gene) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN rs2230392)) (, ,) (NP (NN rs2285524) (NN rs16948627))) (-RRB- -RRB-))) (NP (JJ peripheral) (NN blood)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 61:E05.318.740.600.800 225:E05.337 386:F02.463.425.069 396:G05.380 434:E05.318.308.985.525.375 446:G05.365.795.598 447:C04.557.450.565.575.650 448:E05.393.620.500 449:A12.207.152 450:J01.897|ES| 2:1 7:1 9:1 10:1 14:1 19:1 171:1 336:1 476:1 780:1 875:1 1298:1 1329:1 1476:1 1511:1 1550:1 1551:1 1552:1 1553:1 1554:1 1555:1 1556:1 1557:1 1558:1 1559:1 1560:1 1561:1 1562:1
-1 	|BT| (S (NP (JJ Testis-specific) (NN Fank1) (NN gene) (JJ knockdown) (NN mouse)) (VP (VBP produce) (NP (NN oligospermia)) (PP (IN via) (NP (NN apoptosis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 400:E05.393.335.500 451:C12.294.365.700.508 452:A05.360.444.849|ES| 9:1 19:1 52:1 89:1 464:1 596:1 1563:1 1564:1 1565:1 1566:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (SBAR (IN whether) (S (S (VP (VBG combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam)))) (VP (MD could) (VP (VB offer) (NP (ADJP (ADJP (JJR better)) (ADJP (JJ therapeutic))) (NN effect) (NN combat) (NN HCC) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 74:1 75:1 130:1 131:1 221:1 441:1 541:1 691:1 904:1 908:1 1042:1 1088:1 1089:1 1498:1 1567:1 1568:1
-1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP evaluate) (NP (NN hypermethylation) (JJ spastic) (NN paraplegia-20) (NN promoter) (JJ potential) (NN biomarker) (JJ prognostic) (NN factor) (JJ gastric) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 158:D23.101 225:E05.337 453:C10.597.622.669|ES| 18:1 19:1 83:1 86:1 131:1 185:1 664:1 691:1 827:1 884:1 885:1 890:1 1567:1 1569:1 1570:1
-1 	|BT| (S (S (NP (DT The) (NN aim) (NN work)) (VP (VP (VB evaluate) (SBAR (IN whether) (S (NP (NN TP53) (NN mutation)) (VP (VBN classified) (ADVP (RB functionally)) (ADJP (JJ inactive)))))) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (JJR <)) (CC or) (ADJP (JJ =))) (ADJP (CD 20) (NN %)) (JJ wildtype) (NN transactivation) (NN ability)) (-RRB- -RRB-))) (S (NP (NP (JJ different) (JJ prognostic) (JJ predictive) (NN value) (NN CRC)) (VBN compared) (NN mutation)) (VP (VBD retained) (NP (JJ significant) (NN activity)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 385:F02.784.629.131 395:L01.100 445:I03.946 454:G05.355.315.800|ES| 10:1 14:1 19:1 34:1 50:1 135:1 221:1 245:1 312:1 369:1 399:1 414:1 533:1 691:1 884:1 890:1 1018:1 1248:1 1300:1 1546:1 1567:1 1571:1 1572:1 1573:1 1574:1 1575:1 1576:1 1577:1
-1 	|BT| (NP (NP (NP (DT The) (NN expression) (JJ gastric) (NN cancer) (NN marker) (NN MUC1)) (, ,) (NP (NN MUC2)) (, ,) (NP (NN MUC5AC)) (, ,) (NP (NN oncogene) (NN c-myc)) (, ,) (NP (NN c-met)) (, ,) (NP (NN cyclin) (NN E1)) (, ,) (NP (NN cancer) (NN stem) (NN cell) (NN marker) (NN CD44)) (VP (VBD determined) (NP (NN MGCC3I) (NN cell))))) |ET| |BS|41:A11 158:D23.101 332:A11.872.650|ES| 2:1 18:1 19:1 24:1 86:1 94:1 115:1 210:1 212:1 455:1 534:1 691:1 743:1 1106:1 1578:1 1579:1 1580:1 1581:1 1582:1 1583:1
-1 	|BT| (S (NP (NP (DT The) (NN lung) (NN adenocarcinoma) (NN cell) (NN bearing) (JJ K-ras) (NN gene) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN A549) (NN H820)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB consistently) (JJR higher)) (NN level) (NN cell) (NN motility)) (S (PP (IN without) (NP (NP (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN TKB6) (NN TKB14)) (-RRB- -RRB-)))) (, ,) (NP (NN motility) (NN A549) (NN H820) (NN cell)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN dnAkt) (NN transfection)))))) |ET| |BS|18:G05.365.590 41:A11 122:C14.280.383 217:E05.393.350.810 455:B01.050.150.900.649.147.890|ES| 2:1 9:1 10:1 14:1 19:1 34:1 94:1 124:1 132:1 170:1 249:1 255:1 328:1 364:1 365:1 691:1 746:1 1121:1 1177:1 1195:1 1584:1 1585:1 1586:1 1587:1 1588:1 1589:1
-1 	|BT| (FRAG (NP (DT The) (NN morphology) (CD eight) (NN ASPL-TFE3) (JJ fusion-positive) (JJ renal) (NN tumor)) (, ,) (PP (IN although) (NP (NP (VBG overlapping) (NN aspect) (JJ classic) (NNS ASPS)) (, ,) (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (JJ renal) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN RCC)) (-RRB- -RRB-)))) (, ,) (NP (FW priori) (NN diagnosis) (NN case))))) |ET| |BS|263:E01 274:C04.588.945.947.535 295:C04.557.470.200.025.390|ES| 2:1 7:1 10:1 14:1 19:1 94:1 112:1 304:1 348:1 691:1 855:1 922:1 923:1 934:1 935:1 1037:1 1413:1 1590:1 1591:1 1592:1 1593:1 1594:1 1595:1 1596:1
-1 	|BT| (NP (NP (NP (DT The) (JJ recombinant) (NN plasmid)) (NP (VBN transfected) (JJ human) (ADJP (NN lung) (NN cancer) (NN A549) (NN cell) (JJ liposome-mediated)) (NN method)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 456:D25.479.517 457:G05.360.600|ES| 18:1 19:1 36:1 94:1 328:1 364:1 479:1 691:1 1420:1 1597:1 1598:1 1599:1
-1 	|BT| (S (NP (DT The) (JJ resultant) (NN MLL) (NN fusion) (NN protein)) (VP (VBN known) (VP (VBP mediate) (NP (NN leukaemia) (NN disruption) (JJ normal) (JJ epigenetic) (NN regulation) (NN target) (NN gene) (NN locus))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 142:I01.880.604 361:C04.557.337 458:G05.360.340.024.380|ES| 4:1 9:1 19:1 118:1 160:1 377:1 438:1 556:1 691:1 936:1 1207:1 1263:1 1600:1 1601:1 1602:1 1603:1
-1 	|BT| (S (NP (NP (DT The) (JJ significant) (NN association) (NN SNIP1) (NN c-Myc) (NN staining) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN tissue) (NN array) (NN evidence) (NN activity)) (VP (MD might) (VP (VBN linked)))) (VP (VBZ suggests) (SBAR (S (NP (NN SNIP1)) (VP (MD might) (NP (JJ important) (NN modulator) (NN c-Myc) (NN activity) (NN carcinogenesis))))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 98:A10 110:C04.588.894.797.520.109.220.249 386:F02.463.425.069|ES| 18:1 19:1 38:1 94:1 135:1 207:1 272:1 328:1 331:1 399:1 691:1 694:1 798:1 824:1 902:1 1298:1 1363:1 1604:1 1605:1 1606:1 1607:1
-1 	|BT| (S (NP (DT The) (JJ significant) (NN link) (NN tobacco) (NN loss) (NN p16) (NN locus)) (VP (VBZ identifies) (NP (JJ additional) (JJ genetic) (NN target) (NN smoking) (NN pathogenesis) (NN lung) (NN cancer)))) |ET| |BS|203:G05.360.340.024.340.375.249.375 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 461:F01.145.958.500 462:J01.637.836|ES| 18:1 19:1 32:1 135:1 160:1 328:1 377:1 501:1 691:1 864:1 980:1 1313:1 1608:1 1609:1 1610:1 1611:1
-1 	|BT| (S (NP (DT The) (JJ siRNA-mediated) (NN DEPDC1) (NN depletion)) (VP (VBD resulted) (NP (NP (JJ significant) (NN inhibition) (NN proliferation) (NN delay) (NN cell) (NN cycle) (NN progression) (NN NPC) (NN cell) (NN line)) (, ,) (NP (NN CNE-1) (NN HNE-1))))) |ET| |BS|16:C23.550.291.656 43:F01.145.544 117:D13.150.650.700 353:G04.299.134|ES| 2:1 19:1 48:1 94:1 103:1 135:1 136:1 264:1 299:1 594:1 601:1 691:1 1174:1 1612:1 1613:1 1614:1 1615:1 1616:1
-1 	|BT| (NP (NP (DT The) (JJ unbalanced) (NN translocation)) (, ,) (NP (NN der) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;) (CD q25)) (-RRB- -RRB-) (, ,) (NP (NP (JJ characteristic) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (PRN (-LRB- -LRB-) (NP (NN ASPS)) (-RRB- -RRB-)))) |ET| |BS|439:C04.557.450.590.775 463:C23.550.210.870|ES| 2:1 10:1 14:1 19:1 217:1 336:1 451:1 691:1 923:1 929:1 930:1 931:1 932:1 1117:1 1287:1 1524:1 1617:1 1618:1 1619:1
-1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1
-1 	|BT| (S (NP (DT These) (NNS data) (NN challenge) (NN view) (NN MYH11) (NN passive) (NN differentiation) (NN marker)) (VP (VBG functioning) (S (NP (NN muscle) (NN contraction)) (VP (VBP add) (S (VP (VBG understanding) (NP (JJ intestinal) (NN neoplasia)))))))) |ET| |BS|74:G04.299.151 102:C04.588.274.476.411 158:D23.101 239:F02.463.188.357 375:Z01.639.100 464:G11.427.590.540|ES| 19:1 109:1 215:1 534:1 640:1 792:1 793:1 905:1 1371:1 1626:1 1627:1 1628:1 1629:1 1630:1 1631:1 1632:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP indicate) (SBAR (S (NP (NNP BIM) (NN deletion) (NN polymorphism) (JJ common) (JJ Korean) (NN NSCLC) (NN patient)) (ADVP (RB significantly)) (VP (VBP affect) (NP (JJ intrinsic) (JJ biologic) (NN function) (JJ BH3-only) (NN protein)))))))) |ET| |BS|7:D12.776 50:M01.643 110:C04.588.894.797.520.109.220.249 306:G05.355.600.800 307:G05.365.795 433:F01.470.047 465:D23|ES| 4:1 19:1 33:1 120:1 124:1 329:1 655:1 792:1 927:1 1059:1 1060:1 1479:1 1486:1 1633:1 1634:1 1635:1 1636:1 1637:1
-1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1
-1 	|BT| (NP (NP (DT These) (UCP (S (VP (VBG finding) (PP (VBN suggested) (NP (NN endostatin) (NN gene) (NN therapy))) (, ,) (S (VP (VBG using) (NP (JJ cationic) (JJ vector-mediated) (JJ intravenous) (NN gene) (NN transfer)))))) (, ,) (MD might) (NP (NP (JJ feasible) (NN strategy) (JJ organ-targeted) (NN prevention) (NN regulation)) (JJ possible) (VBN disseminated) (NN cancer))))) |ET| |BS|123:G05.360.337 142:I01.880.604 466:D12.644.276.100.450.750 467:D01.248.497.300|ES| 2:1 9:1 18:1 19:1 130:1 350:1 438:1 792:1 798:1 925:1 927:1 1114:1 1359:1 1474:1 1640:1 1641:1 1642:1 1643:1 1644:1 1645:1 1646:1 1647:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (NP (NP (NN favour) (ADJP (ADJP (JJ non-invasive)) (, ,) (ADJP (JJ ALK-gene))) (NN status)) (JJ pre-screening) (JJ routine) (NN basis) (NNS CTCs)) (VP (VBN isolated) (NP (NP (NN patient) (NN lung) (NN cancer)) (SBAR (S (NP (JJ open) (JJ new) (NN avenue) (JJ real-time) (NN monitoring)) (VP (VBD adapted) (NP (VBN targeted) (NN therapy)))))))))) |ET| |BS|6:G05.360.340.024.340 50:M01.643 52:E02 322:G01.910 468:G07.700.062.133|ES| 2:1 16:1 18:1 19:1 101:1 120:1 130:1 328:1 416:1 712:1 792:1 874:1 1140:1 1361:1 1648:1 1649:1 1650:1 1651:1 1652:1 1653:1 1654:1 1655:1 1656:1 1657:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP implicate) (S (NP (NN SPARC) (NN promoter) (NN methylation) (JJ important) (NN factor) (NN tumorigenesis) (JJ gastric) (NN carcinoma)) (VP (VB provide) (NP (NP (JJ new) (NN insight) (JJ potential) (NN use)) (NP (NNP SPARC) (JJ novel) (NN biomarker) (JJ potential) (JJ clinical) (NN importance) (JJ human) (JJ gastric) (NN cancer)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 36:G02.111.087.029.538 37:D12.776.157.125.715 55:B01.050.150.900.649.801.400.112.400.400 70:A03.556.875.875 158:D23.101 259:D12.776.395.240.150.500 265:C04.557.470.200|ES| 18:1 19:1 36:1 78:1 81:1 82:1 83:1 84:1 86:1 101:1 185:1 304:1 711:1 712:1 792:1 827:1 885:1 891:1 902:1 1141:1 1658:1 1659:1 1660:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ VES-induced) (NN expression) (NN NAG-1) (NN mRNA/protein)) (VP (VBN regulated) (NP (JJ transcriptional/post-transcriptional) (NN mechanism) (NN p38) (JJ kinase-dependent) (NN manner) (NN NAG-1) (JJ chemopreventive/therapeutic) (NN target) (NN prostate) (NN cancer)))))))) |ET| |BS|7:D12.776 52:E02 111:D13.444.735.544 142:I01.880.604 209:G02.111.087.847 469:D08.811.913.696 470:C02.782.160.927|ES| 18:1 19:1 77:1 101:1 115:1 160:1 162:1 792:1 1479:1 1661:1 1662:1 1663:1 1664:1 1665:1 1666:1 1667:1 1668:1 1669:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP reveal) (NP (NN association) (NN SNP) (NN rs7646) (NN NTD) (NN risk))) (VP (VBZ involves) (NP (NP (NN difference) (NN microRNA) (NN regulation)) (, ,) (NP (NN highlight) (NN importance) (JJ genotype-dependent) (JJ differential) (NN microRNA) (NN regulation) (NN relation) (JJ human) (NN disease) (NN risk)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 61:E05.318.740.600.800 142:I01.880.604 184:D13.150.650.319 288:C23.550.288 386:F02.463.425.069 396:G05.380 411:C10.500.680 446:G05.365.795.598|ES| 2:1 19:1 36:1 101:1 171:1 438:1 792:1 857:1 998:1 1298:1 1561:1 1660:1 1670:1 1671:1 1672:1 1673:1 1674:1 1675:1 1676:1 1677:1 1678:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NN ERBB4) (ADJP (ADJP (JJ novel)) (ADJP (JJ therapeutic))) (NN target) (NN subset) (NN CRC))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 259:D12.776.395.240.150.500|ES| 19:1 101:1 160:1 245:1 541:1 792:1 796:1 891:1 1285:1 1679:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (NP (NN IFN-alpha) (NN gene) (NN therapy) (JJ promising) (NN strategy) (NN treat) (NNP HCC) (NN patient)) (JJ concomitant) (NN liver) (NN cirrhosis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 52:E02 104:C04.557.470.200.025.255 357:C06.552.630|ES| 9:1 19:1 101:1 120:1 130:1 441:1 792:1 796:1 836:1 1090:1 1114:1 1199:1 1517:1 1680:1 1681:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (NP (VBN suggested) (NN PSMA6) (NN serf) (JJ attractive) (NN target) (JJ high) (JJ therapeutic) (NN index) (NN lung) (NN cancer)))) |ET| |BS|52:E02|ES| 18:1 19:1 101:1 160:1 178:1 328:1 541:1 721:1 792:1 882:1 925:1 1242:1 1682:1
-1 	|BT| (S (NP (NP (DT This) (NN study)) (VP (VBN designed))) (VP (VBP identify) (SBAR (S (NP (JJ TLR4-mediated) (NN gene) (NN expression) (NN pathway)) (VP (MD may) (VP (VBN used) (SBAR (S (NP (JJ prognostic) (NP (NN indicator) (NN susceptibility) (NN lung) (NN tumorigenesis) (NN mouse))) (VP (VBP provide) (NP (NN insight) (NN mechanism))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 155:G05.355.310 182:A04.411 401:C23.550.291.687 471:D27.720.470.410|ES| 9:1 19:1 52:1 78:1 115:1 131:1 162:1 328:1 383:1 476:1 491:1 711:1 807:1 832:1 884:1 1141:1 1353:1 1683:1 1684:1 1685:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (NP (DT This)) (VP (VBZ suggests) (SBAR (S (NP (NN c-Jun) (NN inhibition)) (VP (MD may) (VP (VB serve) (NP (JJ therapeutic) (NN target) (NN liver) (NN cancer)))))))) |ET| |BS|43:F01.145.544 52:E02|ES| 18:1 19:1 103:1 160:1 331:1 491:1 532:1 541:1 807:1 836:1 1686:1
-1 	|BT| (S (PP (IN Through) (NP (NN combination) (NNS data) (NN mining) (JJ biochemical) (NN assay))) (, ,) (VP (VBD identified) (NP (NP (NN trophinin)) (, ,) (VP (MD could) (VP (VB enhance) (NP (NP (NN cell) (NN invasion)) (, ,) (NP (NP (JJ novel) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer)))))))) |ET| |BS|41:A11 106:E05.091 182:A04.411 259:D12.776.395.240.150.500 472:L01.313.500.750.280.199 473:E01.789.625|ES| 2:1 18:1 19:1 94:1 185:1 310:1 328:1 530:1 620:1 623:1 793:1 884:1 891:1 908:1 1128:1 1129:1 1266:1 1687:1 1688:1 1689:1 1690:1
-1 	|BT| (NP (NP (ADVP (RB Thus)) (, ,) (NP (NP (NN inactivation) (NN p16) (NN gene) (JJ common) (NN event) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (NP (NN mechanism) (NN gene) (NN alteration)) (VP (VBZ differs) (NP (NN smoker) (NN nonsmoker)))))) |ET| |BS|18:G05.365.590 42:G05.355.315.203.374 110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375|ES| 2:1 9:1 18:1 19:1 94:1 162:1 205:1 328:1 655:1 694:1 951:1 1313:1 1314:1 1315:1 1691:1 1692:1 1693:1
-1 	|BT| (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN DAP) (NN kinase) (NN promoter)) (NN methylation)) (VP (VBZ contributes) (NP (NP (NN TRAIL) (NN resistance) (NN NSCLC) (NN cell)) (, ,) (NP (NP (VBN measured) (NN DAP) (NN kinase) (NN promoter) (NN methylation) (NN gene) (NN expression) (NN status)) (NP (CD 11) (NN NSCLC) (NN cell) (NN line)))))))))) (VP (VBD correlated) (NP (NN methylation/expression) (NN status) (NN sensitivity) (NN cell) (NN TRAIL)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 94:A11.251.210 110:C04.588.894.797.520.109.220.249 155:G05.355.310 228:E05.978 474:D08.811.913.696.620.682.700.125.387|ES| 2:1 9:1 19:1 74:1 81:1 83:1 94:1 115:1 221:1 264:1 329:1 416:1 446:1 470:1 607:1 789:1 828:1 845:1 1057:1 1094:1 1694:1 1695:1 1696:1
-1 	|BT| (S (S (VP (TO To) (VP (VB elucidate) (NP (JJ pathogenic) (NN role) (NN MLL) (NN fusion) (NN protein) (NN HOX) (NN dysregulation) (NN leukaemia))))) (, ,) (VP (VBD generated) (NP (JJ novel) (JJ haematopoietic) (JJ lineage-specific) (NN Mll-Een) (NN knock-in) (NN mouse) (NN model)) (S (VP (VBG using) (NP (JJ Cre-mediated) (NN inversion) (NN strategy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 259:D12.776.395.240.150.500 327:G06.930 361:C04.557.337 475:C23.550.210.190 476:A15.378|ES| 2:1 4:1 19:1 31:1 52:1 72:1 73:1 350:1 828:1 891:1 936:1 1114:1 1202:1 1204:1 1207:1 1263:1 1697:1 1698:1 1699:1 1700:1 1701:1 1702:1 1703:1 1704:1
-1 	|BT| (SINV (S (VP (TO To) (VP (VB determine) (NP (NP (JJ genetic) (JJ molecular) (JJ characteristic) (NN tumor)) (VP (VBG carrying) (NP (NN EGFR) (NN gene) (NN mutation))))))) (, ,) (VBD investigated) (S (S (NP (NN EGFR) (NN gene) (NN status) (NN lung) (NN adenocarcinoma)) (VP (VBD evaluated) (NP (NN association) (JJ specific) (JJ characteristic) (NN patient) (NN tumor)))) (, ,) (NP (NP (NP (NP (NX (NN mutation) (NNP KRAS) (NN p53)) (, ,) (NN EGFR) (NN ErbB2) (NN gene) (NN amplification)) (, ,) (NP (NN level) (NN EGFR) (NN HER2) (NN protein)) (, ,)) (NN level) (JJ downstream) (NN effector) (NN EGFR)) (, ,) (NP (JJ phospho-extracellular) (JJ signal-regulated) (NN kinase) (NN phospho-S6) (NN protein))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 7:D12.776 8:C04 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337 247:G01.374.676.530 358:G05.360.340.024.340.375.500.791.295.300 386:F02.463.425.069 388:G05.360.340.024.340.375.500.791.550 392:G05.355.315.250 477:D08.811.913.696.620.682.700.567.249 478:D08.811.913.696.620.682.700.567|ES| 2:1 4:1 7:1 9:1 12:1 19:1 34:1 74:1 120:1 161:1 187:1 188:1 249:1 255:1 328:1 336:1 403:1 416:1 470:1 540:1 560:1 570:1 780:1 828:1 850:1 864:1 921:1 1298:1 1305:1 1705:1 1706:1 1707:1 1708:1
-1 	|BT| (S (NP (PP (TO To) (NP (NN knowledge))) (, ,) (JJ first) (NN study) (NN report) (NN change) (NN lncRNA) (NN expression) (NN profile)) (VP (VBD induced) (NP (NN resveratrol) (NN lung) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 479:G08.686.157.500 480:D13.444.735.790.375 481:D13.444.735.790.375 482:K01.468|ES| 2:1 18:1 19:1 115:1 131:1 200:1 328:1 412:1 417:1 816:1 828:1 1709:1 1710:1 1711:1 1712:1
-1 	|BT| (NP (NP (JJ Tubular) (NN atrophy) (JJ low) (NN netrin-1) (NN gene) (NN expression)) (NP (VBN associated) (VBN delayed) (NN kidney) (NN allograft) (NN function))) |ET| |BS|155:G05.355.310 483:C23.300.070 484:A01.941.500 485:A05.810.453 486:E04.936.864|ES| 9:1 19:1 33:1 115:1 169:1 531:1 1713:1 1714:1 1715:1 1716:1 1717:1 1718:1
-1 	|BT| (S (S (VP (VBG Using) (NP (NP (JJ Mll-Een-expressing) (JJ leukaemic) (NN cell) (NN line)) (VP (VBN derived) (S (NP (NP (NN bone) (NN marrow) (NN Mll) (-LRB- -LRB-) (NN Een) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (: /) (CC +) (-RRB- -RRB-))) (VP (JJ mutant) (NP (NN mouse)))))))) (, ,) (VP (VBD showed) (NP (NP (NN induction) (NN Hox) (NN gene) (JJ leukaemic) (NN cell)) (VP (VBN associated) (NP (NP (JJ hypomethylated) (NN promoter) (NN region)) (NP (JJ aberrant) (JJ active) (NN chromatin) (NN state) (NN Hox) (NN locus))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 41:A11 94:A11.251.210 196:G02.111.570.080.689.675 397:A11.284.430.106.279.345.190.160.180 487:G05.355.315.800 488:A15.382.216|ES| 2:1 9:1 10:1 14:1 19:1 52:1 83:1 94:1 132:1 169:1 197:1 264:1 377:1 526:1 667:1 736:1 811:1 1203:1 1286:1 1346:1 1347:1 1348:1 1719:1 1720:1 1721:1 1722:1 1723:1 1724:1 1725:1 1726:1
-1 	|BT| (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP demonstrate) (SBAR (S (NP (NN dysregulation) (NN HAO2) (JJ early) (NN event) (NN development) (NN HCC)) (VP (MD may) (VP (VB represent) (NP (ADJP (ADJP (JJ useful)) (ADJP (JJ diagnostic))) (JJ prognostic) (NN marker) (JJ human) (NN HCC)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 158:D23.101 263:E01|ES| 5:1 19:1 35:1 36:1 205:1 441:1 491:1 502:1 534:1 799:1 843:1 884:1 903:1 1036:1 1128:1 1202:1 1727:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (NP (NP (JJ allelic) (NN loss) (NNS metaplasias)) (NP (JJ bronchiolar) (NN epithelium) (NN IPF) (NN FISH) (NN analysis) (NN FHIT) (NN gene))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 48:C23.550.589 62:A10.272 260:E01.370.225.562 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500 489:B01.050.150.900.493|ES| 9:1 19:1 32:1 173:1 661:1 843:1 938:1 946:1 1122:1 1222:1 1223:1 1475:1 1728:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD confirmed) (S (NP (JJ balanced) (NN nature)) (-LRB- -LRB-) (NP (NP (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation) (NN fluorescence) (FW situ) (NN hybridization)) (NP (CD seven) (JJ renal) (NN tumor)) (ADVP (RB thus)) (VP (VBN analyzed))) (, ,) (NP (NP (NN contrast)) (ADJP (RB sharply) (JJ unbalanced)) (NN nature) (NN translocation) (NNS ASPS))))))) |ET| |BS|274:C04.588.945.947.535 463:C23.550.210.870 490:E01.370.225.500.620.670.325.350 491:D27.505.259.500 492:K01.637|ES| 2:1 7:1 10:1 14:1 19:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 938:1 1168:1 1334:1 1392:1 1617:1 1618:1 1729:1 1730:1 1731:1 1732:1 1733:1 1734:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP describe) (ADVP (RB herein)) (SBAR (S (NP (NP (CD eight) (RB morphologically) (JJ distinctive) (JJ renal) (NN tumor)) (VP (VBG occurring) (NP (JJ young) (NNS people)))) (VP (VBP bear) (NP (NP (JJ identical) (NN ASPL-TFE3) (NN fusion) (NN transcript) (NN ASPS)) (, ,) (FRAG (NP (NN distinction)) (-LRB- -LRB-) (NP (NP (NN X) (: ;) (CD 17) (-RRB- -RRB-) (NN translocation)) (ADJP (RB cytogenetically) (JJ balanced)) (JJ renal) (NN tumor))))))))) |ET| |BS|274:C04.588.945.947.535 455:B01.050.150.900.649.147.890 463:C23.550.210.870 493:M01|ES| 2:1 7:1 10:1 14:1 19:1 111:1 217:1 843:1 922:1 923:1 928:1 929:1 930:1 935:1 936:1 937:1 1525:1 1590:1 1618:1 1735:1 1736:1 1737:1 1738:1 1739:1 1740:1 1741:1 1742:1 1743:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD explored) (NP (NP (JJ potential) (NN TFPI2) (NN biomarker) (JJ early) (NN detection) (NN CRC)) (VP (VBG using) (NP (NP (NN stool) (JJ DNA-based) (NN assay) (NN patient)) (JJ nonmetastatic) (NN CRC) (JJ average-risk) (NN noncancer) (NN control) (NN candidate) (NN screening)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 61:E05.318.740.600.800 106:E05.091 158:D23.101 198:D13.444.308 333:D01.045 355:A12.459 375:Z01.639.100 494:E01.390|ES| 19:1 120:1 245:1 289:1 310:1 350:1 499:1 827:1 843:1 885:1 1023:1 1128:1 1184:1 1185:1 1188:1 1243:1 1744:1 1745:1 1746:1 1747:1
-1 	|BT| (S (NP (PRP We)) (VP (ADVP (RB previously)) (VP (VBD reported) (SBAR (S (NP (NN kallistatin) (NN gene) (NN therapy)) (VP (VBD suppressed) (NP (NP (NN growth) (NN HCC) (NN tumor) (JJ anti-angiogenic) (NN activity)) (, ,) (NP (NN meloxicam)) (, ,) (NP (JJ selective) (NN COX-2) (NN inhibitor))))))) (, ,) (VP (VBD inhibited) (NP (NN proliferation) (JJ induced) (NN apoptosis) (JJ human) (NN HCC) (NN cell) (NN vitro))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 122:C14.280.383 349:D27.505.519.389.310.500|ES| 2:1 7:1 9:1 19:1 36:1 76:1 89:1 94:1 102:1 130:1 216:1 299:1 307:1 365:1 380:1 399:1 412:1 441:1 843:1 993:1 1088:1 1089:1 1527:1 1748:1 1749:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (S (NP (NNP BIM) (NN intron) (CD 2) (NN deletion) (NN polymorphism) (NN increase) (NN lung) (NN cancer) (NN risk)) (VP (VBZ predicts) (NP (NP (NP (JJ poor) (NN prognosis) (JJ non-small) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN patient))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 159:I01.880.735.634 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 10:1 14:1 18:1 19:1 40:1 120:1 148:1 171:1 328:1 329:1 544:1 545:1 694:1 843:1 1058:1 1059:1 1060:1 1633:1 1750:1 1751:1
-1 	|BT| (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (NP (NP (JJ multiple) (JJ somatic) (NN mutation) (NN CCPRCC) (NN case)) (, ,) (PP (VBG including) (ADJP (JJ recurrent)))) (PRN (-LRB- -LSB-) (NP (NP (CD 3/14) (NN case)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN %)) (-RRB- -RRB-))) (-RRB- -RSB-))) (JJ non-synonymous) (NN T992I) (NN mutation) (NN MET) (NN proto-oncogene)) (, ,) (NP (NP (NN gene)) (VP (VBN associated) (NP (NP (JJ epithelial-to-mesenchymal) (NN transition)) (PRN (-LRB- -LRB-) (NP (NN EMT)) (-RRB- -RRB-)))))))) |ET| |BS|6:G05.360.340.024.340 18:G05.365.590 235:G05.360.340.024.340.375.500.791 443:G05.700.264 495:G04.299.335.500 496:C23.550.291.937 497:G05.365.590.650|ES| 2:1 9:1 10:1 14:1 19:1 34:1 169:1 369:1 388:1 552:1 561:1 563:1 623:1 649:1 843:1 934:1 957:1 1373:1 1378:1 1752:1 1753:1 1754:1 1755:1 1756:1 1757:1 1758:1 1759:1
-1 	|BT| (S (NP (PRP We)) (VP (VBP report) (NP (NP (JJ autophagy) (VBN involved) (JJ NAC1-mediated) (NN resistance) (NN cisplatin)) (, ,) (NP (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN drug) (NN treatment) (JJ ovarian) (NN cancer))))) |ET| |BS|52:E02 67:D26 151:E02.319 390:G04.299.139.399 498:D01.210.375|ES| 2:1 15:1 18:1 19:1 191:1 417:1 476:1 546:1 774:1 843:1 1094:1 1317:1 1760:1 1761:1 1762:1 1763:1
-1 	|BT| (NP (NP (NP (NP (NN Xeroderma) (NN pigmentosum) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN XP-V)) (-RRB- -RRB-))) (NP (JJ rare) (JJ genetic) (NN disease)) (, ,) (NP (VBN characterized) (NN sunlight) (NN sensitivity) (NN predisposition) (JJ cutaneous) (NN malignancy)))) |ET| |BS|401:C23.550.291.687 499:G01.358.500.505.650.836 500:C23.550.291.906 501:C04.834.867 502:C16.320|ES| 2:1 10:1 14:1 19:1 49:1 607:1 864:1 985:1 990:1 998:1 1322:1 1764:1 1765:1 1766:1 1767:1 1768:1 1769:1
-1 	|BT| (S (NP (NP (DT A) (NP (NP (JJ genetic) (NN basis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ well-established) (JJ major) (NN signaling) (NN pathway)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN Wnt-signaling)) (, ,) (NP (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (NN Ras) (NN pathway))) (, ,)) (VP (VBD identified) (NP (JJ essential) (NN HCC) (NN development)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 149:G05.360.340.024.340.364.875.890 503:D12.644.276.374.687|ES| 2:1 10:1 12:1 14:1 19:1 35:1 69:1 102:1 195:1 303:1 304:1 383:1 441:1 462:1 623:1 864:1 1140:1 1770:1 1771:1 1772:1 1773:1 1774:1 1775:1 1776:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN p53) (NNS Mutations)) (JJ common) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN induction) (JJ hepatic) (NN p53) (NN expression))) (VP (VBP cause) (SBAR (S (NP (NN lysis)) (VP (VBD implanted) (NP (NN hepatoblastoma) (NN cell) (JJ chimeric) (NN mouse)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200|ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1
-1 	|BT| (S (ADVP (RB Instead)) (, ,) (NP (NNS data)) (VP (VBD revealed) (NP (NP (NP (NN Skp2)) (VBN regulated) (NN Myc) (NN activity)) (, ,) (NP (JJ oncogenic) (JJ potential) (NN generation) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 142:I01.880.604 279:D27.888.569.100 506:F01.829.263.315 507:D12.776.157.743|ES| 2:1 19:1 275:1 303:1 304:1 399:1 793:1 827:1 953:1 1664:1 1784:1 1785:1 1786:1 1787:1
-1 	|BT| (NP (NP (NP (NN Loss) (NN miR-122) (NN cause) (JJ chronic) (NN steatohepatitis)) (NP (JJ spontaneous) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 508:C06.552.241|ES| 19:1 283:1 303:1 304:1 1779:1 1788:1 1789:1 1790:1 1791:1
-1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN MAT1A)))) (VP (VBD reduced) (NP (JJ hepatic) (NN S-adenosylmethionine) (NN content) (NN hyperplasia)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ nonalcoholic) (NN steatohepatitis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 232:D02.886.030.676.180 509:C06.552.241.519 510:C23.550.444|ES| 19:1 376:1 452:1 583:1 648:1 838:1 1506:1 1791:1 1792:1 1793:1 1794:1 1795:1 1796:1
-1 	|BT| (S (NP (NP (NP (NN MicroRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (, ,) (NP (ADJP (RB highly) (JJ abundant)) (JJ liver-specific) (NN miRNA)) (, ,)) (VP (VBP act) (NP (NP (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 104:C04.557.470.200.025.255 184:D13.150.650.319 206:G05.360.340.024.340.375.249 242:A03.620|ES| 2:1 7:1 10:1 14:1 19:1 246:1 303:1 304:1 441:1 626:1 700:1 840:1 1789:1 1797:1 1798:1 1799:1
-1 	|BT| (S (NP (NP (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma1)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma1)) (-RRB- -RRB-))) (JJ important) (NN transcription) (NN factor)) (VP (VBN involved) (NP (NN atherosclerosis) (NN progression)))) |ET| |BS|16:C23.550.291.656 166:D12.776.930 511:C14.907.137.126.307 512:D12.776.826.239 513:C14.907.137.126|ES| 10:1 14:1 19:1 48:1 185:1 487:1 774:1 902:1 1800:1 1801:1 1802:1 1803:1 1804:1
-1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
-1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD investigated) (NP (JJ gross) (NN alteration) (NN series) (NN rodent/human) (NN liver) (NN tumor) (JJ human) (JJ tumorigenic) (NN cell) (NN line)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623|ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1
-1 	|BT| (S (NP (DT A) (NN Cox) (JJ proportional) (NN hazard) (NN model)) (VP (VBD showed) (NP (NP (NN IFITM3) (NN expression) (JJ independent) (JJ prognostic) (NN factor)) (NP (JJ disease-free) (NN survival) (NN patient) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 50:M01.643 516:E05.318.740.500.700 517:E01.789.200|ES| 18:1 19:1 69:1 72:1 113:1 115:1 120:1 132:1 185:1 274:1 696:1 883:1 884:1 1810:1 1811:1 1812:1 1813:1
-1 	|BT| (NP (NP (NP (DT A) (JJ novel) (NN GSK-3) (NN beta-C/EBP) (JJ alpha-miR-122-insulin-like) (NN growth) (NN factor) (CD 1) (NN receptor) (JJ regulatory) (NN circuitry)) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500 518:D08.811.913.696.620.682.725.400.185 519:D05.500.117.875|ES| 19:1 36:1 69:1 98:1 102:1 185:1 186:1 303:1 304:1 891:1 1814:1 1815:1 1816:1 1817:1 1818:1
-1 	|BT| (S (NP (DT A) (JJ previous) (NN investigation)) (VP (VBD indicated) (NP (NP (NN ATA) (JJ effective) (VBG inhibiting) (NN growth) (NN breast) (NN cancer)) (NP (RB especially) (NN cell) (NN HER2) (NN overexpression))))) |ET| |BS|41:A11 45:G07.700.320.249 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 122:C14.280.383 225:E05.337 520:C10.228.140.252.190.530.060|ES| 18:1 19:1 23:1 69:1 94:1 102:1 152:1 188:1 345:1 880:1 1497:1 1541:1 1639:1 1819:1 1820:1
-1 	|BT| (S (NP (JJ Additional) (NN qRT-PCR) (NN analysis)) (VP (VBD revealed) (S (NP (JJ gradual) (NN elevation) (VBG circulating) (NNS miRNAs)) (-LRB- -LRB-) (NP (FRAG (NP (FW i.e.) (, ,) (NN let-7a) (, ,) (NN let-7f) (, ,) (NN miR-34a) (, ,) (NN miR-98) (, ,) (NN miR-331) (, ,) (NN miR-338) (NN miR-652) (-RRB- -RRB-) (NN progress) (NN hepatocarcinogenesis))))))) |ET| |BS|184:D13.150.650.319 448:E05.393.620.500|ES| 2:1 10:1 14:1 19:1 275:1 661:1 876:1 888:1 900:1 1110:1 1623:1 1821:1 1822:1 1823:1 1824:1 1825:1 1826:1 1827:1 1828:1 1829:1 1830:1 1831:1
-1 	|BT| (NP (NP (NN AIM) (: :)) (S (VP (TO To) (VP (VB define) (NP (NP (JJ biological) (NN contribution) (NNP Hras) (NN mouse) (NN hepatocarcinogenesis)) (, ,) (VP (VBN quantified) (S (FW vivo) (NP (NN interaction) (JJ mutant) (NNP Hras) (JJ genetic) (NN alteration)) (ADVP (RB frequently)) (VP (VBN associated) (NP (NP (NN liver) (NN cancer)) (, ,) (PP (VBG including) (NP (NP (NN overexpression) (NP (NN transcription) (NN factor) (NN c-myc) (JJ epidermal) (NN growth) (NN factor) (NN receptor) (NN ligand) (VBG transforming) (NN growth) (NN factor) (NN alpha))) (PRN (-LRB- -LRB-) (NP (NN TGFalpha)) (-RRB- -RRB-))))))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 64:D08.811.913.696.620.682.725.400.009.300 167:H01.158.273 170:D27.720.470.480 521:D08.811.277.040.330.300.400.500.600 522:D12.644.276.382.750 523:D12.776.260.676|ES| 2:1 10:1 14:1 18:1 19:1 52:1 102:1 104:1 152:1 169:1 184:1 185:1 186:1 378:1 440:1 455:1 487:1 561:1 618:1 698:1 811:1 828:1 836:1 864:1 900:1 951:1 959:1 1360:1 1772:1 1832:1 1833:1 1834:1 1835:1 1836:1 1837:1
-1 	|BT| (S (NP (NN Alteration) (NN Apc) (NN gene)) (VP (VBN shown) (NP (NP (NN play) (JJ important) (NN role)) (JJ PhIP-induced) (JJ IQ-induced) (NN rat) (NN colon) (NN carcinogenesis)))) |ET| |BS|3:C04.557.470.035.215.100 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 9:1 19:1 31:1 113:1 207:1 237:1 238:1 280:1 849:1 902:1 1838:1 1839:1 1840:1
-1 	|BT| (NP (NNS Alterations) (NP (NP (NN hMSH2) (NN gene)) (VP (VBN linked) (NP (ADJP (QP (RB approximately) (CD 60)) (NN %)) (JJ hereditary) (JJ nonpolyposis) (NN colon) (NN cancer) (NN case))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 524:C04.588.274.476.411.307.190|ES| 9:1 18:1 19:1 113:1 369:1 934:1 1363:1 1841:1 1842:1 1843:1 1844:1 1845:1 1846:1
-1 	|BT| (FRAG (SBAR (IN Although) (NP (NP (NP (VBN induced) (NN cell) (NN death)) (VBN regarded) (JJ major) (NN component) (NN p53) (JJ tumor-suppressive) (NN activity)) (, ,) (S (ADVP (RB recently)) (VP (VBD found) (SBAR (S (NP (JJ sustained) (NN p53) (NN activation) (JJ subsequent) (NN DNA) (NN damage)) (VP (VBZ promotes) (NP (JJ inflammation-associated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 8:C04 134:G04.299.139 525:C23.550.470 526:G05.355.180|ES| 2:1 12:1 19:1 37:1 94:1 107:1 177:1 225:1 298:1 399:1 411:1 412:1 462:1 666:1 772:1 900:1 1021:1 1319:1 1521:1 1847:1 1848:1 1849:1
-1 	|BT| (NP (NP (NP (NN Amplification) (NN HER2)) (PRN (-LRB- -LRB-) (NP (NP (NN ErbB2)) (, ,) (NP (NN c-Neu))) (-RRB- -RRB-))) (NP (NP (NN proto-oncogene) (NN breast) (NN cancer)) (NP (VBN associated) (JJ poor) (NN prognosis) (JJ high) (NN relapse) (NN rate)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 159:I01.880.735.634 163:E01.789 235:G05.360.340.024.340.375.500.791 527:C23.550.291.937|ES| 2:1 10:1 14:1 18:1 19:1 23:1 41:1 169:1 178:1 188:1 544:1 545:1 563:1 1012:1 1705:1 1850:1 1851:1
-1 	|BT| (S (NP (NP (NN Androgen) (JJ receptor-induced) (NN tumor) (NN suppressor)) (, ,) (NP (NN KLLN)) (, ,)) (VP (VBZ inhibits) (SBAR (S (NP (NN breast) (NN cancer) (NN growth)) (ADVP (RB transcriptionally)) (VP (VBZ activates) (NP (JJ p53/p73-mediated) (NN apoptosis) (NN breast) (NN carcinoma))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 45:G07.700.320.249 122:C14.280.383 206:G05.360.340.024.340.375.249 528:D12.776.826.750.150|ES| 2:1 7:1 18:1 19:1 23:1 89:1 102:1 301:1 304:1 615:1 700:1 1478:1 1852:1 1853:1 1854:1 1855:1
-1 	|BT| (NP (NP (NN Antitumor) (NN function) (NN microRNA-122) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|104:C04.557.470.200.025.255 184:D13.150.650.319|ES| 19:1 33:1 303:1 304:1 1856:1 1857:1
-1 	|BT| (S (NP (NN Astrocyte) (JJ elevated) (NN gene-1) (NN c-Myc)) (VP (VBP cooperate) (VP (VBP promote) (NP (NN hepatocarcinogenesis) (NN mouse))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 529:A08.637.200|ES| 19:1 52:1 474:1 679:1 756:1 824:1 900:1 1858:1 1859:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (SBAR (: :) (S (S (NP (NNS Mutations) (NN APC) (NN gene)) (VP (VBP result) (VP (VBN increased) (S (NP (NN propensity)) (VP (VB develop) (NP (JJ intestinal) (NN neoplasia))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (JJ complete) (NN understanding) (NN mechanism)) (VP (VBG resulting) (NP (NN tumor) (NN formation)))) (VP (VBD remained) (ADJP (JJ elusive))))))) |ET| |BS|8:C04 18:G05.365.590 20:G03.495 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 102:C04.588.274.476.411 239:F02.463.188.357|ES| 2:1 7:1 9:1 11:1 19:1 43:1 47:1 101:1 104:1 109:1 162:1 172:1 217:1 384:1 640:1 648:1 777:1 905:1 1046:1 1387:1 1410:1 1777:1 1778:1 1860:1 1861:1
-1 	|BT| (S (SBAR (IN Because) (S (NP (NN Notch) (NN signaling) (VBN implicated) (NN colon) (NN cancer) (NN tumorigenesis)) (VP (VBZ protects) (NP (NP (NN cell) (NN apoptosis)) (VP (VBG inducing) (NP (JJ prosurvival) (NN target))))))) (, ,) (VP (VBD hypothesized) (SBAR (S (NP (NP (NN inhibition) (NN Notch) (NN signaling) (NN gamma-secretase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN GSI)) (-RRB- -RRB-))) (VP (MD may) (NP (VB enhance) (NP (NN chemosensitivity) (NN colon) (NN cancer) (NN cell)))))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 41:A11 43:F01.145.544 69:G02.111.087.800 125:D08.811.277.656.300.032|ES| 2:1 10:1 14:1 18:1 19:1 78:1 89:1 94:1 103:1 113:1 160:1 195:1 256:1 380:1 386:1 491:1 977:1 1690:1 1750:1 1862:1 1863:1 1864:1 1865:1 1866:1 1867:1
-1 	|BT| (S (PP (IN By) (NP (JJ immunohistochemical) (NN analysis))) (, ,) (NP (CD 20) (CD 38) (NN case) (JJ undifferentiated) (NN type)) (VP (VBD advanced) (NP (NP (NN stomach) (NN cancer) (NN K-sam)) (JJ positive)) (, ,) (PP (IN whereas) (NP (NP (NN none) (CD 11) (NN case)) (SBAR (S (NP (VBN differentiated) (JJ intestinal) (NN type)) (VP (VBD revealed) (NP (NN K-sam) (NN staining))))))))) |ET| |BS|47:A03.556.124 74:G04.299.151 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 109:1 233:1 275:1 372:1 543:1 661:1 782:1 801:1 803:1 804:1 934:1 997:1 1057:1 1167:1 1605:1 1868:1 1869:1 1870:1 1871:1
-1 	|BT| (S (ADVP (RB Collectively)) (, ,) (NP (NN miR-122) (NN depletion)) (VP (VBZ facilitates) (NP (NP (NN cystogenesis) (NN hepatocarcinogenesis) (NN mouse) (NN DEN) (NN challenge)) (VP (VBG up-regulating) (NP (NP (JJ several) (NN gene)) (VP (VBN involved) (NP (NP (NN proliferation)) (, ,) (NP (NN growth) (NN factor) (NN signaling)) (, ,) (NP (NN neovascularization)) (, ,) (NP (NN metastasis))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 69:G02.111.087.800 113:C04.697.650 150:Z01.542.248.960 344:M01.438 530:C23.550.589.500|ES| 2:1 9:1 19:1 52:1 102:1 185:1 195:1 262:1 299:1 774:1 806:1 900:1 1371:1 1613:1 1789:1 1872:1 1873:1 1874:1 1875:1 1876:1 1877:1
-1 	|BT| (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN loss) (JJ multifunctional) (NN miR-122)) (VP (VBZ contributes) (NP (NP (JJ malignant) (NN phenotype) (NN HCC) (NN cell)) (, ,) (NP (NN miR-122) (JJ mimetic) (RB alone) (NP (NN combination) (JJ anticancer) (NN drug))) (NP (JJ promising) (JJ therapeutic) (NN regimen) (NN liver) (NN cancer))))))))) |ET| |BS|41:A11 52:E02 67:D26 80:G05.695 104:C04.557.470.200.025.255 231:C04.557.465.625.600.380.590 242:A03.620 531:E02.183.750 532:E02.183|ES| 2:1 18:1 19:1 32:1 94:1 101:1 191:1 236:1 241:1 441:1 530:1 541:1 796:1 802:1 836:1 845:1 1517:1 1789:1 1872:1 1878:1 1879:1 1880:1 1881:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (NN outcome) (NN study)) (VP (VBP represent) (NP (JJ significant) (NN contribution) (JJ current) (NN understanding) (JJ preventive) (NN mechanism) (NN quercetin) (JJ early) (NN stage) (NN liver) (NN cancer) (NN development)) (, ,) (S (VP (VBG demonstrating) (NP (NP (NN addition)) (VP (VBN known) (VP (JJ proapoptotic) (ADJP (ADJP (JJ characteristic)) (, ,) (SBAR (S (NP (NN flavonoid)) (VP (VBZ modulates) (NP (NP (NN expression) (JJ critical) (NN cell) (NN cycle) (NN regulator)) (NN peroxisome) (NN proliferator) (VBD activated) (NN receptor-alpha) (NN activity)))))))))))))) |ET| |BS|239:F02.463.188.357 242:A03.620 353:G04.299.134 473:E01.789.625 533:D03.383.663.283.266.450.284.777 534:D03.383.663.283.266.450 535:H01.770.644.145.431 536:D12.776.826.239.500|ES| 2:1 18:1 19:1 35:1 94:1 104:1 115:1 131:1 135:1 162:1 163:1 175:1 235:1 336:1 399:1 468:1 527:1 547:1 556:1 601:1 606:1 691:1 799:1 825:1 836:1 905:1 1128:1 1129:1 1360:1 1882:1 1883:1 1884:1 1885:1 1886:1 1887:1 1888:1 1889:1
-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (NP (DT These) (JJ clinical) (JJ mechanistic) (NN finding)) (VP (VBP indicate) (SBAR (S (NP (NP (NN IFITM3) (JJ direct) (JJ transcriptional) (NN target) (NN KLF4)) (VBN dysregulated) (NP (NN KLF4)) (NN expression)) (VP (VBP lead) (NP (JJ aberrant) (NN IFITM3) (NN expression)) (, ,) (S (ADVP (RB thus)) (VP (VBG contributing) (NP (NN colon) (NN cancer) (NN progression) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 86:D01.268.556.435 113:C04.697.650 209:G02.111.087.847|ES| 2:1 18:1 19:1 48:1 84:1 104:1 113:1 115:1 160:1 254:1 559:1 696:1 792:1 806:1 927:1 1259:1 1295:1 1334:1 1479:1 1725:1 1882:1 1890:1 1891:1 1892:1
-1 	|BT| (NP (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (JJ Acute) (NN ablation) (NN GSK3beta) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ activates) (NP (JJ p53-dependent) (NN apoptosis)))) (SBAR (S (VP (VBZ antagonizes) (NP (NN tumor) (NN growth))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 45:G07.700.320.249|ES| 7:1 17:1 18:1 19:1 88:1 89:1 91:1 94:1 102:1 104:1 239:1 301:1 794:1 1893:1 1894:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VB identify) (NP (NP (NP (JJ novel) (NN candidate) (NN mouse) (NN gene)) (, ,) (NP (NN Zfp277)) (, ,)) (SBAR (WHNP (WP$ whose) (NN expression) (NN pattern)) (S (NP (JJ compatible) (NN role)) (VP (VBG mediating) (NP (JJ divergent) (NN effect) (NN Chrm3) (NN Chrm1) (NN gene) (NN ablation) (JJ murine) (JJ intestinal) (NN neoplasia))))))))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 47:A03.556.124 102:C04.588.274.476.411 259:D12.776.395.240.150.500 537:G05.360.340.024.340.375|ES| 2:1 9:1 19:1 31:1 52:1 75:1 91:1 101:1 104:1 109:1 115:1 239:1 260:1 627:1 640:1 658:1 761:1 832:1 891:1 919:1 1243:1 1895:1 1896:1 1897:1 1898:1 1899:1
-1 	|BT| (S (NP (NN CRC)) (VP (VBD initiated) (NP (NP (NN mutation) (NN tumor) (NN suppressor) (NN gene)) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-))) (, ,) (NP (NN beta-catenin) (NN gene)))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 18:G05.365.590 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 206:G05.360.340.024.340.375.249|ES| 2:1 7:1 9:1 10:1 11:1 14:1 19:1 34:1 57:1 58:1 59:1 60:1 245:1 700:1 1900:1
-1 	|BT| (S (NP (NN CRC) (NN xenograft)) (VP (VBD differed) (NP (NP (NP (NP (NN p53) (NN status)) (PRN (-LRB- -LRB-) (NP (JJ wt) (NN muf)) (-RRB- -RRB-))) (NN microsatellite) (NN instability) (NN phenotype)) (PRN (-LRB- -LRB-) (NP (NP (NN MSI)) (CC +) (NP (JJ altered))) (-RRB- -RRB-))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 80:G05.695 92:E04.936.764 93:A01.941.875 538:C23.550.362.590|ES| 10:1 12:1 14:1 19:1 236:1 245:1 265:1 416:1 693:1 1299:1 1332:1 1901:1 1902:1 1903:1 1904:1
-1 	|BT| (NP (NP (JJ Differential) (NN effect) (JJ oncogenic) (NN K-Ras) (NN N-Ras) (NN proliferation)) (, ,) (NP (NN differentiation) (NN tumor) (NN progression) (NN colon))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 16:C23.550.291.656 51:C04.588.274.476.411.307.180 74:G04.299.151 279:D27.888.569.100|ES| 2:1 7:1 13:1 19:1 48:1 75:1 113:1 215:1 299:1 953:1 1905:1 1906:1
-1 	|BT| (S (NP (NN Differentiation) (NN therapy) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ recombinant) (NN adenovirus)) (VP (VBG carrying) (NP (NN hepatocyte) (JJ nuclear) (NN factor-4alpha) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 52:E02 74:G04.299.151 104:C04.557.470.200.025.255 247:G01.374.676.530 539:D20.215.894.899.024 540:D12.776.260.262 541:C02.256.076 542:B04.280.030|ES| 9:1 19:1 52:1 130:1 303:1 304:1 850:1 1256:1 1420:1 1907:1 1908:1 1909:1 1910:1
-1 	|BT| (S (S (NP (JJ Ectopic) (NN expression) (NN miR-155)) (VP (VBD promoted) (NP (NP (NP (NN growth) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN cell)))) (, ,) (IN whereas) (S (NP (NN depletion)) (VP (VBD inhibited) (NP (NN cell) (NN growth))))) |ET| |BS|41:A11 45:G07.700.320.249 104:C04.557.470.200.025.255 107:G05.355.315.202 122:C14.280.383|ES| 2:1 10:1 14:1 19:1 94:1 102:1 115:1 303:1 304:1 305:1 365:1 372:1 441:1 1613:1 1911:1 1912:1
